

REVIEW



Insect antimicrobial peptides: potential weapons to counteract the antibiotic resistance

M. D. Manniello¹ · A. Moretta¹ · R. Salvia^{1,2} · C. Scieuzzo^{1,2} · D. Lucchetti³ · H. Vogel⁴ · A. Sgambato^{3,5} · P. Falabella^{1,2}

Received: 23 November 2020 / Revised: 19 January 2021 / Accepted: 29 January 2021 / Published online: 17 February 2021
© The Author(s) 2021

Abstract

Misuse and overuse of antibiotics have contributed in the last decades to a phenomenon known as antibiotic resistance which is currently considered one of the principal threats to global public health by the World Health Organization. The aim to find alternative drugs has been demonstrated as a real challenge. Thanks to their biodiversity, insects represent the largest class of organisms in the animal kingdom. The humoral immune response includes the production of antimicrobial peptides (AMPs) that are released into the insect hemolymph after microbial infection. In this review, we have focused on insect immune responses, particularly on AMP characteristics, their mechanism of action and applications, especially in the biomedical field. Furthermore, we discuss the Toll, Imd, and JAK-STAT pathways that activate genes encoding for the expression of AMPs. Moreover, we focused on strategies to improve insect peptides stability against proteolytic susceptibility such as D-amino acid substitutions, N-terminus modification, cyclization and dimerization.

Keywords Immune system · Antibacterial peptides · Resistant bacteria · Mechanism of action · Signaling pathways

Introduction

The antibiotic resistance as a global concern

Today, the identification of novel antibacterial therapeutics represents an auspicious perspective [1]. In fact, the inappropriate consumption and overuse of the first-line maintenance

therapies have favored, in the last decades, an increasing selection of antibiotic-resistant pathogens. This phenomenon, together with the lack of availability of new molecules, represents real issues in health care [2, 3]. The multi-drug-resistant pathogens, such as ESKAPE (i.e. *Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter*) species, are considered practically resistant to most of the available antibiotics and have played a critical role in the growth of nosocomial infections [4, 5]. Moreover, the World Health Organization (WHO) has recently updated the priority list constituted of 12 bacterial pathogens against which there is a need to develop new antibiotics. The WHO list is divided into three categories according to the urgency of need for new antibiotics: critical, high, and medium priority. The category with a critical priority comprises the Gram-negative species *P. aeruginosa*, and *A. baumannii*, both carbapenem-resistant bacteria frequently associated with severe and often lethal diseases such as bloodstream infections and pneumonia. Several Gram-positive species constitute the high priority list, among which *S. aureus* methicillin-resistant (MRSA), and vancomycin-intermediate and resistant [6].

M. D. Manniello, A. Moretta, R. Salvia and C. Scieuzzo contributed equally to this work.

✉ P. Falabella
patrizia.falabella@unibas.it

¹ Department of Sciences, University of Basilicata, Via dell'Ateneo Lucano 10, 85100 Potenza, Italy

² Spinoff XFlies S.R.L, University of Basilicata, Via dell'Ateneo Lucano 10, 85100 Potenza, Italy

³ Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy

⁴ Department of Entomology, Max Planck Institute for Chemical Ecology, Hans-Knöll-Straße 8, 07745 Jena, Germany

⁵ Centro di Riferimento Oncologico Della Basilicata (IRCCS-CROB), Rionero in Vulture (PZ), Italy

The increasing rate of antibiotic resistance represents a particularly challenging issue in the treatment of topical infections. Several complications such as chronic skin and soft tissue infections which can complicate the clinical course of ulcers, diabetic foot infections, post-surgical infections, and burn wounds are characterized by a progressive worsening of their clinical outcome, when antibiotic-resistant pathogens are involved. Likewise, the Gram-negative bacterium *A. baumannii* has been reported as responsible for a variety of antibiotic-resistant infections such as wound, skin, and urinary tract infections, but also pneumonia and bacteraemia [7].

Bacterial infections of the lower respiratory tract, often related to bronchiectasis, represent an increasing and common chronic respiratory disease, associated not only with cystic fibrosis (CF) lung disease but also to chronic obstructive pulmonary disease. The clinical course of an antibiotic-resistant bronchiectasis can face, therefore, a progression of the health-condition worsening, due to the establishment of an infection-inflammation cycle uncontrollable by available drugs [8–10]. Lung infections associated with bronchiectasis may evolve to respiratory failure and death. Moreover, reduced quality of life and an increase in healthcare costs can worsen the patient compliance [11].

It is noteworthy that the successful management of bacterial infections is the product of combined actions of the host immune response and the administration of antibiotics. Hence, deficiencies of the host immune system and/or reduced efficacy of antibiotics due to the presence of resistant pathogens might, unfortunately, contribute to switching towards a persistent infection. Chronic bacterial infections are associated with increased morbidity and mortality from the infection itself as well as an increased risk of dissemination of disease which is a life-threatening condition difficult to treat, especially in the presence of antibiotic-resistant pathogens.

Therefore, along with the irresponsible use of antibiotics, the related resistance issue towards the most commonly used molecules represents a global concern [12]. The aim to find alternative drugs has demonstrated to be a real challenge, as well [13, 14].

The biofilm issue

Bacterial pathogens have established various ways to defeat the host's immune response so that bacterial virulence has been analyzed for decades. In nature, bacteria are physically grouped in clusters and embedded by extracellular polymeric substances [15]. In clinical settings, pathogen bacteria can effortlessly survive when colonizing surfaces (e.g. on wounds, scar tissue, medical implants), since sessile cells are less prone than planktonic to interact with the ordinarily used antimicrobials. Biofilms are bacterial communities

embedded within an extracellular matrix and adherent to a surface. Biofilm formation is one of the main mechanisms of surviving, and it regards a wide range of microbes that commonly cause chronic infections [16]. One essential feature of biofilms is the intrinsic resistance of the bacterial community to the host immune system by decreasing efficacy of antibodies and antimicrobial peptides (AMPs) as well as phagocytic uptake within it thus hampering leukocyte-mediated killing. Moreover, the biofilm extracellular matrix component can partly limit the diffusion of antibiotics, thus, reducing their antimicrobial efficacy. The most relevant clinical biofilm-forming bacteria comprise the Gram-negative *A. baumannii*, *Escherichia coli*, *K. pneumoniae*, and *P. aeruginosa*, along with Gram-positive *S. aureus* and the less virulent *Staphylococcus epidermidis*.

Over 80% of chronic wounds are related to bacterial biofilms, in which the most commonly isolated pathogens are *S. aureus* and *P. aeruginosa* [17–23]. Humans are transporters of *S. aureus* infections; a range of 20–75% of humans demonstrated to be intermediate carriers. Several human body sites, such as nasal cavities, pharynx, perineum, and skin represent the primary sites for colonization. Commonly, the colonization by *S. aureus* causes no serious health problems in healthy individuals. However, the risk of developing *S. aureus* infection increases in the case of hospitalized patients with wounds, burns, and chronic ulcers [14]. *P. aeruginosa* is a ubiquitous bacterium that colonizes the natural environment near humans. Nevertheless, it represents a crucial but also one of the most resistant pathogens in CF lung disease [24]. Both representative species have been often associated with a biofilm mode of growth when isolated in the lower airways and portrayed as highly recalcitrant to the antibiotic treatments [25–27].

Failure of the common pharmacological approaches

Multiple reasons for clinical failure can be mentioned when referring to antibiotic resistance. Poor pharmacokinetics of drugs in infection sites, or the bacterial phenotype of persistence, associated with the ability to survive in protected niches such as biofilms, foster the clinical failure. As mentioned above, specific bacteria may persist during the antibiotic treatment when drugs are administered at concentrations that should be lethal. Hence, this behavior may cause prolonged and recurrent infections [11]. Thus, antibiotic resistance is associated with higher medical costs, longer hospitalization, and increased mortality. To fight antibiotic resistance, a great effort has been devoted in the last decades to the development of new molecules, acting as antibiotics. Nevertheless, only a few new classes of antibiotics reached market availability in the last 3 decades, and others are still in human clinical trial. The clinical outcomes of resistant infections are also related to the host response to infection

and to pathogen-derived toxic compounds. *S. aureus*, for example, can produce molecules able to counteract neutrophil's action, i.e. preventing the adhesion to the blood vessels and their transmigration into the site of infection or eliciting cell death [28].

Regarding the skin infection management, the increasing issue related to resistance to the commonly used antibiotics mainly concerns the involvement of the deeper tissues which can cause the clinical worsening of wounds with clearly systemic infection risk. *S. aureus* is also associated with catheter-related bacteremia and intubation-related infections, such as pneumonia and bloodstream infections. Since the increasing resistance of bacterial pathogens often needs the use of more toxic agents to be counteracted, the antimicrobial therapy by topical application involves the use of not only suitable (e.g. considering toxic antibiotics) but also higher dosing as well [13, 29–31].

Natural sources of antimicrobials

Screening of natural products has allowed the identification of some of the most active drugs. Biologically, active natural peptides can represent useful alternatives being characterized by high therapeutic efficacy, a low probability of resistance emerging in target cells, and limited side effects. To this aim, the exploitation of new compounds and the identification of their mechanisms of action is essential for further development. Antimicrobial peptides (AMPs), small molecules composed of 10–100 amino acid residues produced by all organisms, are attractive candidates for the design of new antibiotics because of their natural antimicrobial properties and a low propensity for the development of resistance [32]. Indeed, these natural peptides have retained their activity over the course of the evolution, triggering little or no resistance, and might represent a valuable alternative to classical drugs. Moreover, several evidence suggest that they can display anticancer activities characterized by a strong selectivity and efficacy on cancer cells so that many of them are also indicated as anticancer peptides (ACPs) [33–35]. Therefore, AMPs and ACPs are the focus of a large number of studies aimed at developing new antibiotics against multi-resistant bacteria (MDR) and new anticancer drugs AMPs are usually cationic and amphipathic and their structure includes both hydrophobic and hydrophilic moieties with a highly positive net charge (ranging from +2 to +9). They can be effective on a wide spectrum of microorganisms and can display powerful antimicrobial activities against antibiotic-resistant bacteria. Insects are an almost inexhaustible source of biologically active compounds. Natural products deriving from insects have been used for centuries in traditional medicine and still represent an essential source of healing substances in developing countries.

Insects as natural sources of antimicrobials

Overview

Considering over one million described species, insects represent the largest class of organisms, due to their ability to adapt to recurrent changes and their resistance to a broad spectrum of pathogens [36, 37]. This resistance skill is related to their immune system, based exclusively on the innate immune response, which allows a broad and fast response to invading organisms [1, 38–40]. With the aim to prevent the entrance of pathogens within the hemocoel cavity, the first protection is represented by physical barriers such as the cuticle, the intestinal wall, and the tracheas (Fig. 1) [40, 41].

In recent years, an increasing number of insect AMPs have been proving useful in several applications concerning the pharmaceutical as well as the agricultural fields. Moreover, insect AMPs aroused great interest for their biomedical application thanks to the growing number of identified peptides that can inhibit human pathogens. AMPs susceptible pathogen bacteria include multidrug-resistant *E. coli*, *K. pneumoniae*, *Bacillus coagulans*, *Citrobacter freundii*, *Francisella tularensis*, *Streptococcus sanguinis*, and *S. aureus* [41–45]. Besides, some insect AMPs can also inhibit virus replication such as the two alloferons from the blowfly *Calliphora vicina*. These compounds have been demonstrated to be active against both human influenza viruses A and B [46]. Furthermore, melittin, peptide derivative from *Apis mellifera*, shows antiviral activity against herpes simplex virus 1 (HSV-1) [47]. Several fungi are also susceptible to insect AMPs including *Pichia pastoris*, *Aspergillus fumigatus*, *Cryptococcus neoformans*, *Botrytis cinerea*, *Fusarium* spp., *Neurospora crassa*, and *Trichoderma viride* [48–50]. Given the increasing bacterial resistance to antibiotics, there is a great interest in verifying the AMPs suitability for the treatment of recalcitrant bacterial infections and killing of resistant bacteria. Several reports have highlighted that insect-derived AMPs can represent good candidates as alternatives to conventional antibiotics [51–53]. However, the treatments to inhibit pathogenic infections using cecropins, positively charged AMPs originally isolated from insects, for example, have suffered from some limitations. Indeed, they represent a target of human elastase produced by neutrophils, which are recruited during infections, or can be subjected to protease degradation [54, 55].

Insect AMPs represent a highly promising alternative to overcome medical problems associated with antibiotic resistance. Several studies have been performed using insect cecropins in the functionalization of biomaterials used in biomedicine, such as hydrogels and polyurethane




Fig. 1 Schematic representation of insect immunity system. The first protections against the host invasion are physical barriers, including cuticle and epidermis. When pathogens succeed in overcoming these barriers, cellular and humoral immune responses are triggered,

involving melanization, AMP production, and/or reaction mediated by hemocytes. Adapted from Lu and St. Leger, 2016, created with BioRender.com

surfaces [56, 57]. Moreover, cecropin expression in transgenic plants can confer resistance to bacterial and fungal pathogens [58, 59]. Transgenic expression of an insect cecropin (sarcotoxin-IA) and defensin (*Galleria mellonella* named gallerimycin) in tobacco also confers resistance to fungi [60].

Organization of insect immunity system

All invertebrates including insects have a defense mechanism exclusively based on a powerful innate immune system, which allows a general and rapid response to different invading organisms [61]. The first protection against pathogens is represented by physical barriers such as the cuticle, the intestinal wall including the peritrophic membrane, and the tracheas [62]. If the foreign organisms pass through these defensive barriers, penetrating the hemocoel, the immune response is triggered. The innate immune system is conserved across all organisms comprising cellular responses and humoral responses. In insects, cellular immune responses are mediated by hemocytes, the cellular component of hemolymph responsible for nodulation, encapsulation and phagocytosis of invading pathogens. On the other hand, the haemocytes together with the fat body cells are also involved in the mechanisms of the humoral response

that includes AMP synthesis, the enzymatic cascade that regulates the activation of hemolymph coagulation and melanization, and the production of reactive oxygen (ROS) and nitrogen (RNS) species [63].

The clear separation between humoral and cellular response is more conventional than functional; some of the humoral factors regulate the activity of haemocytes and, at the same time, haemocytes are the source of several molecules involved in the humoral response. Furthermore, they often share the same signal transduction pathways, even if activated by different stimuli [38, 64].

Among the humoral immune response in insects the production of melanin, a highly toxic phenolic biopolymer is involved both in the defense against pathogens and in the repair of cuticular wounds to prevent the loss of hemolymph [65]. Melanogenesis is regulated by the pro-phenoloxidase (proPO) system, a cascade of serine proteases and inhibitors of serine proteases that finely control the activation of proPO, the precursor of phenoloxidase (PO), after the recognition of an external elicitor [66]. Many data have shown that proPO is synthesized and accumulated in haemocytes and, when necessary, released by a lytic process which does not necessarily lead the cell to death [67]. Other studies have shown that proPO is localized on the surface of hemocytes. This localization could facilitate the deposition of melanin

directly on the foreign agent [68, 69]. Melanin is a very toxic compound and its systemic diffusion would be extremely harmful for the insect: the localization of its synthesis is essential to ensure the survival of the insect during the activation of melanogenesis [70]. Melanogenesis also generates cytotoxic intermediates, such as quinones and semiquinones, which favor the synthesis ROS and RNS. Moreover, these intermediates, alone or in combination with ROS and RNS, are cytotoxic molecules that participate in the elimination of the pathogen [71].

Cellular immune response is mediated by hemocytes. In most species of different orders, such as *Lepidoptera*, *Diptera* (except *Drosophila*), *Orthoptera*, *Blattoidei*, *Coleoptera*, *Hymenoptera*, *Hemiptera*, and *Collemboli*, the hemocytes are differentiated into granulocytes, plasmacytocytes, spherulocytes, and oenocytoids [64, 72]. In *Lepidoptera*, granulocytes and plasmacytocytes, which represent more than 50% of the circulating hemocytes, show adhesive ability. Plasmacytocytes are also involved in the production of AMPs as well as in the release of extracellular matrix components [39]. The other two components of hemocytes, the spherulocytes, which carry cuticle components, and the oenocytoids, containing precursors of the activation cascade of the PO, have not any adhesive ability [39].

Phagocytosis, mediated by hemocytes, includes the recognition and encapsulation of foreign agents through

modifications of the hemocyte cytoskeleton and ends with the transport of the phagocytized material into the phagosomes where it is completely degraded thanks to the action of hydrolase, ROS and nitric oxide [72] (Fig. 2). In most insect orders, both granulocytes and plasmacytocytes are responsible for phagocytosis while in *Drosophila melanogaster* this role is played by plasmacytocytes alone [64, 72]. During the immune response, the nodulation process is activated when a large number of bacteria cannot be phagocytized by a single hemocyte. In this process, several kinds of hemocytes recognize and surround microorganisms, thus forming complexes that may or may not undergo melanization [73] (Fig. 2). In the encapsulation process, hemocytes adhere to surfaces of invading agents that are too big to be phagocytized, such as parasites, protozoa or nematodes consequently forming a capsule, made up of several cell layers, that undergoes melanization. Inside the capsule, the pathogenic organism is killed by asphyxiation or by the production of cytotoxic free radicals [72]. Granulocytes and plasmacytocytes are involved in capsule formation in *Lepidoptera* [64, 72] while this role is played by plasmacytocytes and lamellocytes in *D. melanogaster* [74] (Fig. 2).




Fig. 2 Insects innate immune response can be humoral or cellular. Humoral immunity consists of AMPs production by the fat body and/or hemocytes; hemolymph melanization and production of the reactive oxygen and nitrogen species. Cellular immunity consists of phagocytosis, nodulation and encapsulation processes. Phagocytosis determines the internalization of foreign agents by the hemocytes and the transport of the phagocytized material into the phagosomes

where it is degraded. Nodulation occurs when bacteria are too much to be incorporated by a single hemocyte. Indeed, several hemocytes together recognize and surround foreign agents. In the encapsulation process, hemocytes create a capsule made up of several cell layers that undergoes melanization. Inside the capsule, the pathogenic organism is killed by asphyxiation and/or production of cytotoxic free radicals [64, 72].

Activation of the insect immune response

The triggering of the insect immune response is generated only when the exogenous agent is recognized, identifying specific and preserved molecules located on the pathogen surface defined as pathogen-associated molecular patterns (PAMPs) [75]. PAMPs are molecular components potentially present in all microorganisms but absent in higher organisms. Examples of PAMPs comprise Gram-positive lipoteichoic acid and peptidoglycan, Gram-negative bacteria lipopolysaccharide (LPS), and fungi β -1,3-glucan [76]. These non-self-molecules are recognized by specific receptors (named pattern-recognition proteins, PRPs), which can be both humoral and cellular. Immunolectins, peptidoglycan recognition proteins (PGRPs), and Gram-negative binding proteins (GNBPs) are proteins circulating in the hemolymph and capable of recognizing specific antigens [40]. Peptidoglycan-recognition protein LC (PGRP-LC) and integrins, on the other hand, are receptors found on the surface of immune cells, which, respectively, recognize surface components of Gram-negative bacteria and the RGD motif (Arg-Gly-Asp) [36, 40]. The latter is found in the proteins of the extracellular matrix and in some soluble proteins such as collagen, fibronectin, and laminin. The binding of integrins to the RGD motif, for example, represents the first step for the recognition of exogenous agents. Furthermore, it is involved in bacterial phagocytosis or in the encapsulation process [40]. When the receptors, both humoral and cellular, bind to pathogen-associated molecules, specific immune responses are triggered based on the type of invader [1, 39, 40]. The humoral immune response includes the production of AMPs, the enzymatic cascade that regulates the activation of hemolymph coagulation, melanization, and the production of reactive oxygen as well as nitrogen species (often indicated as ROS and RNS, respectively) [71] (Fig. 2).

Due to the relevance of AMP function in insects, in the following section, we focused on insect AMPs with a special emphasis on their classification, overviewing their structural and functional characteristics, along with reviewing the signaling pathways which activate the encoding AMP genes and their mechanism of action.

Overview of insect antimicrobial peptides

Insects can interact with the ecosystem using chemical substances. Besides, a variety of species can contribute to investigate the potential of new molecules [77]. Although it is possible to find smaller or larger peptides in nature, AMPs comprise small molecules whose amino acid composition ranges from 12 to 50 amino acids [53].

AMPs are involved in several defence-related processes such as the binding and the neutralization of endotoxins, the

modulation of the immune responses to infection, and the pathogens killing [78]. The first insect AMP, the cecropin, was identified in the 1980 from the pupae of *Hyalophora cecropia* [42, 79]. AMPs show a wide range of antibacterial, antiviral, anticancer, and antifungal activity [80–82]. In the last few years, the number of identified insect peptides has considerably increased, thanks to the published insect genome, transcriptome, and proteomic datasets (OMIC analysis). Mass spectrometry methodologies are adopted for the analysis of insect hemolymph, extracted from bacteria-induced larvae [83]. Both peptides and proteins have been considered as a promising choice to treat various diseases. It is now known that the adoption of AMPs is a promising alternative to substitute or support the current antimicrobial approach. Moreover, 3180 AMPs have been identified from different kingdoms, among which bacteria (i.e. 355 bacteriocins), fungi (20 AMPs), plants (352 AMPs), and animal sources (2356 AMPs) [84] (<http://aps.unmc.edu/AP/>). So far, the Antimicrobial Peptide Database is currently reporting 311 out of the 3180 insect-derived AMPs [84]. Surely, the OMIC analysis can also contribute to increasing the number of peptides or proteins isolated by insects that could have antimicrobial activity and become new potential AMPs [85].

Most insect AMPs are cationic molecules due to the presence of basic residues with activities against bacteria. According to their amino acid sequences and structures, AMPs can be classified in four different groups: cysteine-rich peptides (e.g. defensins), the α -helical peptides (e.g. cecropins), glycine (Gly)-rich proteins (e.g. attacins), and proline-rich peptides (e.g. drosocins) [86, 87]. Number of AMPs in insects can widely vary among species: for example, 57 putatively active peptides were identified in *Hermetia illucens*, while very few peptides were identified in aphids [88, 89]. *H. illucens* is one of the most promising sources for AMPs, as the larval instar feed on vegetal and animal decaying organic substrates. Larvae are capable of producing several AMPs, which protect the insect from the pathogens in the substrate and are able to restore substrate health conditions, reducing the bacterial load of pathogenic species such as *E. coli* and *Salmonella enterica* [90, 91]. Recently a stomoxyZnH1 from *H. illucens* was cloned and expressed in bacterial cells and tested against different bacterial and fungal strains, resulting in inhibition of *S. aureus* and *E. coli* (growing bacteria), as well as *Rhizoctonia solani* and *Sclerotinia sclerotiorum* (Lib.) de Bary (fungi) [92].

Defensins (cysteine-rich AMPs)

Defensins are small cationic peptides due to the presence of basic amino acids, particularly arginine [93]. They consist of about 34–51 residues and contain six conserved cysteines (Cys) which form three intramolecular disulfide bridges. Insect defensins have been identified in several insect orders

such as Hemiptera, Coleoptera, Diptera, Hymenoptera, and Lepidoptera, but also in the ancient order of Odonata, suggesting that they might derive from a common ancestor gene [94].

From a structural point of view, defensins show an N-terminal loop, an α -helix, followed by an antiparallel β -sheet, as shown in Fig. 3 for the defensin lucifensin (2LLD, PDB code) from *Lucilia sericata* (ATCDLLSGTGVKH-SACAAHCLLRGNRGGYCNGRAICVCRN) [95–98].

Two intramolecular disulfide bonds connect the β -sheet and the α -helix, forming a Cys-stabilized alpha beta (CS $\alpha\beta$) structure [97]. Considering the insect defensins, the Cys are linked as Cys1—Cys4, Cys2—Cys5, and Cys3—Cys6 [99]. For example, Defensin A sequence from *Protophormia terraenovae* is shown in Fig. 4, and Fig. 5.

Insect defensins are particularly active against Gram-positive bacteria such as *S. aureus*, *Bacillus subtilis*, *Micrococcus luteus*, and *Bacillus megaterium*. Nevertheless, some of them have also shown antimicrobial activity against Gram-negative bacteria such as *E. coli* [100, 101]. In Table 1, the major insect defensins with reported antimicrobial activity are listed.





Fig. 3 Structural representation of lucifensin, a defensin antimicrobial peptide identified in *Lucilia sericata*, obtained from the Protein Data Bank [95]. The N-terminal loop is shown magenta; the α -helix region in red and the antiparallel β -sheet in green. The image has been generated with UCSF CHIMERA software [98]

Fig. 4 Disulfide bonds amongst Cys of insect Defensins A from *Protophormia terraenovae*



Cecropins (α -helical AMPs)

AMPs belonging to the cecropin family represent the most abundant linear α -helical AMPs in insects [38]. They were isolated for the first time from hemolymph of the lepidopteran *Hyalophora cecropia*. Before maturation, insect cecropins are composed by a range between 58 and 79 amino acids. The active forms contain between 34 and 55 residues and are mainly active against Gram-negative bacteria, and, to a lesser extent, against Gram-positive bacteria [112, 113]. It has been also demonstrated that some cecropins can exhibit (i) antifungal activity, (ii) a low toxicity against normal mammalian cells, and (iii) a weak, or absent in some cases, hemolytic effect against mammalian erythrocytes [114]. Moreover, most cecropins are subjected to amidation of the C-terminus, a post-translational modification that increases their antimicrobial activity [81]. Circular dichroism analyses demonstrated that in aqueous solution, cecropins assume a random coiled structure. However, upon the interaction with microbial membranes, cecropins adopt a α -helical conformation [115, 116]. In Fig. 6a, b, the structures of papiliocin (2LA2, PDB code) from *Papilio xuthus*, and GK cecropin-like peptide (2MMM, PDB code) from *Aedes aegypti*, respectively, are shown.

Several insect cecropins have been studied so far from both a structural and a biological point of view, evaluating their in vitro activity. For example, cecropin A has a stabilized α -helical structure and has been shown to reduce both NADP⁺ and glutathione levels, inducing oxidative stress by forming ROS, but its mechanism of action is still unknown [117, 118].

Cecropin A shows activity against the fungus *Beauveria bassiana* in silkworm larvae [119] but cecropin B, a linear cationic peptide, shows the highest and wide antibacterial activity among the cecropins family [120]. It has been reported that cecropin B decreases the bacterial load of *E. coli* and the concentration of plasma endotoxin it has exhibited antifungal activity against *Candida albicans* [115, 121]. Some cecropins also show anti-inflammatory activity [122, 123]. Inflammation is a protective response of a tissue triggered by pathogen infection and involved in the reparative processes [124]. In Table 2, the major insect cecropins with reported antimicrobial activity are listed.




Fig. 5 Structural representation of disulfide bonds in lucifensin. The loop is shown in cyan, the α -helix region in red, and the antiparallel β -sheet in orange while the cysteine residues, and the disulfide bonds are in purple. The image has been generated using UCSF CHIMERA software [98]

Attacins

Attacins are Gly-rich proteins, first purified from the hemolymph of *H. cecropia* bacteria-immunized pupae. Attacins are produced as pre-pro-proteins with a signal peptide, a pro-peptide, an N-terminal attacin domain and two Gly-rich domains, called G1 and G2 domains [130].

They can be divided in two groups: the acidic (i.e. attacin E, and F), and basic (i.e. attacins A–D) attacins [131]. Even though attacins are encoded by two different genes [132] and they have been identified in lepidopteran and dipteran species [133–137], they show high similarity in the amino acid sequences.

They are mostly active against Gram-negative bacteria, particularly *E. coli* and some Gram-positive bacteria. For example the attacin peptide from *Spodoptera exigua*, is active against *E. coli* and *Pseudomonas cichorii* but also against Gram-positive *Bacillus subtilis* and *Listeria monocytogenes* [138, 139].

Glycine-rich AMPs

Gloverins are Gly-rich peptides identified in the *Lepidoptera*

Table 1 Examples of insect defensins with reported antimicrobial activity

Peptide (species)	SwissProt accession number	Antimicrobial activity	Reference
Defensin (<i>Phlebotomus duboscqi</i>)	P83404	Gram-positive bacteria	[102]
Tenecin 1 (<i>Tenebrio molitor</i>)	Q27023		[103]
Defensin (<i>Bombus pascuorum</i>)	P81462	Gram-positive and Gram-negative bacteria	[104]
Coprisinc (<i>Copris tripartitus</i>)	A9XFZ7		[105]
Defensin 1 (<i>Acalolepta luxuriosa</i>)	Q9BK52		[106]
Defensin A (<i>Anomala cuprea</i>)	P83669	Gram-positive bacteria	[107]
Defensin B (<i>Anomala cuprea</i>)	P83668	Gram-positive and Gram-negative bacteria	
Defensin (<i>Calliphora vicina</i>)	C0HJX7	Gram-positive bacteria	[108]
Royalisin (<i>Apis mellifera</i>)	P17722		[109]
Defensin (<i>Pyrrhocoris apterus</i>)	P37364	Gram-positive and Gram-negative bacteria	[110]
Defensin (<i>Oryctes rhinoceros</i>)	O96049	Gram-positive bacteria	[111]

insect order and synthetized as pre-pro-proteins [140]. They

Fig. 6 Structural representation of (a) papiliocin, identified in *Papilio xuthus* insect and (b) GK cecropin-like peptide from *Aedes aegypti*, obtained from the Protein Data Bank [95]. Images have been generated with UCSF CHIMERA software [98]




Table 2 Examples of insect cecropins with reported antimicrobial activity. All the listed cecropins are active against both Gram-positive and Gram-negative bacteria

Peptide (species)	SwissProt accession number	Antimicrobial activity	Reference
Cecropin A (<i>Spodoptera litura</i>)	Q9XZG9	Gram-positive and Gram-negative bacteria	[125]
Cecropin B (<i>Spodoptera litura</i>)	Q9XZH0		
Stomoxyn (<i>Stomoxys calcitrans</i>)	Q8T9R8		[126]
Cecropin A (<i>Hyalophora cecropia</i>)	P01507		[38]
Cecropin B (<i>Hyalophora cecropia</i>)	P01508		[113]
Cecropin D (<i>Hyalophora cecropia</i>)	P01510		[127]
Cecropin A (<i>Bombyx mori</i>)	Q27239		[113]
Cecropin B (<i>Bombyx mori</i>)	P04142		
Cecropin D (<i>Bombyx mori</i>)	O76146		
Papiliocin (<i>Papilio xuthus</i>)	D8L127		[128]
Cecropin B (<i>Antheraea pernyi</i>)	P01509		[129]
Cecropin B (<i>Antheraea pernyi</i>)	P01511		

Diptericin (*Phormia terraenovae*)

DLHIPPPDNKINWPQLSGGGGGSPKTGYDININAQQK

Fig. 7 Sequence of a glycine-rich peptide, Diptericin from *Phormia terraenovae*. Highlighted in red the glycine residues

are basic molecules, and, in aqueous solution, they take a random coil structure, assuming an α -helical structure in a hydrophobic environment [141]. The first gloverin peptide was purified from the hemolymph of *Hyalophora gloveri* pupae [141]. Gloverin peptides are mostly active against Gram-negative bacteria, particularly *E. coli*, but some of them exhibit antimicrobial activity against Gram-positive bacteria, fungi, and viruses [140, 142]. Gloverin peptide identified in *Manduca sexta*, although exhibiting activity against the Gram-positive bacteria *Bacillus cereus*, *Saccharomyces cerevisiae*, and *C. neoformans*, show no activity against *E. coli* [140].

Diptericins are another class of Gly-rich peptides. Diptericins A–C have been isolated from immunized larvae of *Phormia terraenovae* (Fig. 7), in *Sarcophaga peregrina* and in *D. melanogaster* [143–145]. Prolixicin, a 21 amino acid peptide, has been isolated from *Rhodnius prolixus* and it is released by midgut tissues after the hemolymph bacterial infection [39].

Proline-rich AMPs

Proline-rich AMPs have a high content of Pro residues. Among them, Lebocins are proline-rich peptides first isolated from the hemolymph of *Bombyx mori* immunized with *E. coli* [146]. Lebocins show antimicrobial action against Gram-positive and Gram-negative bacteria, as well as against some fungi. They were identified in *B. mori*, and require the O-glycosylation for their full activity mainly against *Acinetobacter sp.* and *E. coli*

Drosocin (*Drosophila melanogaster*)

GKPRPYYSPRPTSHPRPIRV

Fig. 8 Sequence of a proline-rich peptide, Drosocin from *Drosophila melanogaster*. Highlighted in red the proline residues

[146]. Other proline-rich AMPs have been identified, such as drosocin, produced by *D. melanogaster* (Fig. 8). Drosocin is an O-glycosylated 19 amino acid peptide and shows a significant sequence homology with Apidaecin IB peptide, isolated from *A. mellifera* [147, 148]. Apidaecins are involved in the honeybee humoral defense against microbial invasion [148].

Moreover, a 26-residue proline-rich immune-inducible linear peptide called Metchnikowin, has been identified in *D. melanogaster*, by Levashina et al. [149]. However, this peptide is not active against Gram-negative bacteria, whereas it exhibits antimicrobial activity against Gram-positive bacteria and fungi. Concerning the antifungal activity, Metchnikowin targets the iron-sulfur subunit (SdhB) of succinate-coenzyme Q reductase [150] and it interacts with the fungal enzyme (1,3)-glucanosyltransferase Gel1 (FgBGT) which is involved in fungal cell wall synthesis [150].




Fig. 9 Schematic representation of Toll (a), Imd (b), and JAK-STAT (c) signaling pathways. In insects, the Toll pathway is mainly involved in fungi and Gram-positive bacteria detection. Pathogen recognition peptidoglycan recognition proteins (PGRP) activate a serine proteases cascade, involving ModSP and Grass proteins, which in turn, cleaving the inactive form of Spätzle protein, switch on the molecule. These interactions initiate protease cascades. Spätzle activates the dimer Toll receptor, which, in turn recruits cytoplasmic proteins (dMyD88, Tube, and Pelle) involved in the activation of Cactus signaling. In normal cellular condition, Cactus protein is coupled with the Nuclear Factor kappa B (NF- κ B) transcription factors Dorsal-related immunity factor (DIF) and Dorsal, but following the Toll pathway activation, it is phosphorylated, detached from DIF and Dorsal and degraded. Then, both DIF and Dorsal can translocate in the nucleus and induce the transcriptional regulation of specific AMP genes (A) [160]. The insect Imd signaling pathway is activated following the binding between PGRP-LC and meso-diaminopimelic acid (DAP)-type peptidoglycan of Gram-negative and some Gram-positive bacteria. The Imd protein is activated following the cleavage by the Fas-associated death domain (FADD) and the death related ced-3/Nedd2-like caspase (DREDD). The K63-polyubiquitin chains help to link this complex with TAK1 and TAB2 proteins that, in turn, act on the IKK complex, which phosphorylates the NF- κ B-like nuclear factor Relish. Consequently, TAK1 and TAB2 proteins are activated, that in turn, act on the IKK complex, composed of Immune Response Deficient 5 (IRD5) and Kenny (Key). This activated complex cleaves Relish. In this way, the Rel DNA-binding domain is released from the C-terminal ankyrin-repeat/I κ B-like domain, and translocates to the nucleus inducing specific AMP genes transcription (B) [160]. In insect, JAK/STAT pathway is activated when the cytokine receptor, Domeless (Dome), bind the Unpaired (Upd) cytokines which induces the JAK tyrosine kinase Hopscotch (Hop) to phosphorylate itself and the Dome cytoplasmic component. Simultaneously, the signal transducer and activator of transcription at 92E (Stat92e) bind to the phospho tyrosines on Dome, and they are phosphorylated by Hop. Phosphorylated Stat92e separates itself from the receptor, dimerize and relocate into the nucleus, where it induces the transcription of Thioester-containing protein genes (Teps) and Turandot (Tot) genes. Proteins derived from the transcription of these genes are involved in phagocytosis and melanization processes [160, 161]

Nedd2-like caspase (DREDD). The K63-polyubiquitin chains help to link this complex with TAK1 and TAB2 proteins that, in turn, act on the IKK complex, which phosphorylates the NF- κ B-like nuclear factor Relish. Consequently, TAK1 and TAB2 proteins are activated, that in turn, act on the IKK complex, composed of Immune Response Deficient 5 (IRD5) and Kenny (Key). This activated complex cleaves Relish. In this way, the Rel DNA-binding domain is released from the C-terminal ankyrin-repeat/I κ B-like domain, and translocates to the nucleus inducing specific AMP genes transcription (B) [160]. In insect, JAK/STAT pathway is activated when the cytokine receptor, Domeless (Dome), bind the Unpaired (Upd) cytokines which induces the JAK tyrosine kinase Hopscotch (Hop) to phosphorylate itself and the Dome cytoplasmic component. Simultaneously, the signal transducer and activator of transcription at 92E (Stat92e) bind to the phospho tyrosines on Dome, and they are phosphorylated by Hop. Phosphorylated Stat92e separates itself from the receptor, dimerize and relocate into the nucleus, where it induces the transcription of Thioester-containing protein genes (Teps) and Turandot (Tot) genes. Proteins derived from the transcription of these genes are involved in phagocytosis and melanization processes [160, 161]

Signaling pathways and mechanisms of action

AMP gene activation—Toll, Imd, and JAK-STAT pathways

Several signaling molecules are activated after detection of foreign microorganisms by pattern-recognition receptors. Among these, the main pathways are the Immune Deficiency (Imd), the JAK-STAT, and the Toll pathways, which have been well described in *D. melanogaster* (Fig. 6) [151–153]. Antigens of both Gram-positive bacteria and fungi can induce the Toll pathway by activating cellular immunity (Fig. 9a) [153]. Afterward, the signaling pathways involved in humoral immune responses are activated, leading to the release of AMPs, such as drosomycin, by the fat body [39]. The Toll pathway activates the nuclear factor κB (nuclear factor kappa-light-chain enhancer of activated B cells—NF-κB) reacting in response to stress stimuli, such as in the presence of bacterial or viral antigens [153, 154]. The transmembrane receptor Toll is activated by the extracellular cytokine-like polypeptide, called Spätzle, previously cleaved by serine protease cascades that, in turn, is triggered by the recognition of foreign agents [155]. Specifically, the Toll activation is mediated by peptidoglycan recognition proteins (PGRPs), Gram-negative binding protein (GNBP) 1 in the case of Gram-positive bacterial infection, whereas Toll activation is mediated by GNBP 3 in the case of fungal infections [156, 157]. Toll signaling is activated when Spätzle binds the Toll receptor (Fig. 9a) [158]. The dimerization of the intracytoplasmic TIR (toll-interleukin receptor) domains consequently starts, leading then to the binding of the adaptor protein Myeloid differentiation primary response 88 (MyD88) [153]. This protein binds the adaptor protein, Tube, which recruits the protein kinase Pelle for its autophosphorylation and phosphorylation and degradation of an IkB inhibitor, Cactus. The NF-κB transcription factors Dorsal or Dif are then translocated into the nucleus where they activate the transcription of AMPs [159].

Concerning the infection signaling by Gram-negative bacteria, the Imd signaling pathway is activated when the PGRP-LC receptors bind meso-diaminopimelic acid (DAP)-type peptidoglycan 2 (Fig. 9b). Imd binds to the Fas-associated protein with death domain (FADD), while the caspase called DREDD (FADD-death-related ced-3/Nedd2-like protein) is recruited to cleave the Imd protein, which is then activated by K63-ubiquitination [163, 164]. The K63-polyubiquitin chains recruit TAK1 (transforming growth factor beta (TGF-β)-activated kinase 1), which activates the IKK complex involved in the phosphorylation of the NF-κB-like nuclear factor Relish. After Relish cleavage and

phosphorylation, it reaches the nucleus where it activates transcription of specific AMPs, such as dipterincin (Fig. 9b) [165].

In the Janus kinase-signal transducer and activator of transcription (JAK-STAT), JAKs are activated after the binding of a cytokine to its receptors and phosphorylate-specific tyrosine residues on the cytoplasmic part of the receptor and these residues then bind to STAT molecules [160, 166] (Fig. 9c). The STAT tyrosine residues are then phosphorylated by JAKs, leading to dimers formation and to the translocation into the nucleus, where they bind the promoters of their target genes [167]. In *D. melanogaster*, the JAK-STAT pathway ligands consist of three cytokine-like proteins called unpaired (upd), upd2 and upd3 [146]. The Dome receptor [168] binds to a single JAK molecule, hopscotch (hop) [169], and one STAT transcription factor, Stat92E for the induction of immune response genes [170].

However, the humoral immune response in *D. melanogaster* is principally controlled by the Toll and Imd pathways leading to the production of AMPs [153].

Insect AMP mechanism of action

Most insect AMPs show a positive net charge which allows the interaction with the negatively charged molecules exposed on the bacterial cell surfaces, i.e. LPS of Gram-negative and teichoic acids of Gram-positive bacteria, respectively. Then, the electrostatic attraction is the first interaction that occurs between peptides and cell membranes [86, 171]. Hence, AMPs can generate an unbalancing of ion flows across the membrane (i.e. depolarization). This process consequently produces permeabilization of the bacterial membrane [172]. After reaching the onset concentrations, the formation of pores and the subsequent cell death can be induced (Fig. 10). As demonstrated for other peptides deriving from different organisms, insect AMPs can also act through a non-membranolytic mechanism (Fig. 11) [78]. In this case, AMPs lead to bacterial death by interacting with intracellular targets, as observed, for example, for the Temporin L peptide derived from *Rana temporaria*. It inhibits cell division by binding the FtsZ protein that is the key factor of the divisome complex and is essential in Z-ring formation in *E. coli* [173]. Insect proline-rich peptides are also able to bind other intracellular targets such as the chaperone DnaK or the protein synthesis apparatus [174] (Fig. 11).

We focused our main attention on the mechanism of action of defensins, cecropins and attacins AMPs. Insect defensins may lead to bacterial death through the membranolytic mechanism leading to pore formation on the bacterial membranes or can interact with phospholipids to induce microheterogeneity in the lipid membrane [175, 176] (Fig. 10a). LPS could represent a barrier for the antibacterial activity of insect defensins. Indeed, it has been demonstrated




Fig. 10 Schematic representation of AMP interaction with the bacterial membrane. Membranolytic mechanisms begin with adsorption of AMP on target cell membrane (a). In the barrel-stave model peptides permeate through the bilayer (b); in the toroidal pore mechanism, peptides interact with the head groups of the lipids, induce the bilayer

curvature and perpendicularly insert into the membrane bilayer (c); in the carpet model, peptides cover all the membrane the membrane, the peptide non-polar side chains bind the membrane hydrophobic core while the polar residues with the lipid phosphates, forming micelles with the fragmented membrane (d)

that *E. coli* strains with mutants of LPS are more sensitive to insect defensins [177].

Several studies have been performed to understand cecropin mechanism of action and to identify the functions of specific residues. Most mature cecropins have a tryptophan (Trp) residue in the first or second positions, which confers antimicrobial activity to the peptide [1, 72, 171, 176]. It has been demonstrated that the Trp2 and Phe5 residues in papilioxin peptide, identified in *Papilio xuthus*, are essential for the peptide interaction with LPS in the outer membrane and then for the permeabilization of the inner membrane of Gram-negative bacteria [175].

Although cecropins do not interact with specific receptors, several mechanisms have been proposed to explain the pore formation (Fig. 10). Among these, the carpet model, characterized by high peptide concentration, that leads to the membrane disruption by micelles formation (membranolytic mechanism) (Fig. 10d), is the most accredited. In particular, the interaction via the carpet mechanism assumes that peptides cover the membrane and interact only with the lipid head groups. They associate with the bacterial membrane and then the peptide non-polar side chains fit in the membrane hydrophobic

core while the polar residues interact with the lipid phosphates, forming micelles with the fragmented membrane [178, 179]. At low peptide concentrations, cecropins can form channels or pores in specific sections of the membrane [115, 178, 180].

The toroidal pore mechanism, considered as a part of the membranolytic mechanism, consists of peptides insertion, perpendicularly into the bacterial membrane bilayer, a subsequent interaction with the head groups of the lipids to finally induce the bilayer curvature (Fig. 10c). Instead, the barrel-stave pore formation model suggests that the peptides permeate through the bilayer [181] (Fig. 10b). It has been observed that cecropins identified in *H. cecropia* form a barrel (barrel-stave model), which penetrate the bacterial membrane. Concerning peptides shorter than 22 residues they, however, act through a toroidal pore model, in which the pore is composed by both lipids and peptides [178].

Furthermore, several studies described the ability of AMPs to overpass the membrane using a specific interaction with bacterial phosphatidylethanolamine present at higher concentration onto the bacterial membranes [172]. Nonetheless, it is widely accepted that AMPs can target




Fig. 11 Schematic representation of AMP non-membranolytic mechanism. In this case, AMPs can penetrate into the bacterial cell without membrane break, causing bacterial death by interacting with intracellular

molecular targets, including DNA and proteins involved in cellular division or protein synthesis

several functions of the bacterial cytoplasm, including the synthesis of nucleic acids, proteins, enzymes, and cell walls. The ability to interfere with several bacterial biosynthetic pathways explain the difficulty in developing resistance towards AMPs [182–184].

Regarding attacin peptides, they can inhibit *E. coli* cells growth by preventing the synthesis of several bacterial porins, which are outer membrane proteins, such as OmpA, OmpC, and OmpF by binding to LPS without penetrating the inner membrane or cytoplasm [139]. Moreover, a well-known peptide, called melittin, is a 26 residues peptide toxin identified in *A. mellifera* venom and is effective against bacteria [185, 186]. It has a strong antibacterial activity against several bacteria and it binds to membrane surfaces leading to pore formation and then to cell lysis [187].

Stability improvements of peptides against proteolytic susceptibility

Overview

The main disadvantage of peptide structure is the susceptibility toward both host and microbial proteolytic

degradation, that may occur before the AMPs can exhibit the pharmacological effect [188]. Therefore, different strategies have been exploited so far.

Peptide drug candidates must deal with bioavailability and biodistribution issues. In reaching the biophase, AMPs have shown low stability in plasma, low oral bioavailability due to protease susceptibility, and rapid hepatic as well as renal clearances. Biopharmaceutical issues, such as high hydrophilicity and a poor ability to cross physiological barriers, must also be considered. Medicinal chemistry can also help with modifications of the wild-type sequence to improve the poor molecular stability or to modulate the conformational flexibility [189, 190]. For instance, the first studies about drosocin, an O-glycosylated AMP from the fruit fly (i.e. *D. melanogaster*), demonstrated inactivity when injected into *E. coli*-infected mice. Drosocin demonstrated a loss of stability and consequently a loss of antibacterial activity [15, 147]. A series of subsequent studies showed that serum stability of the molecule was improved by considering the non-glycosylated drosocin analogs, which reported an extended half-life in mouse serum and improved activity against Gram-negative pathogens *E. coli* and *K. pneumoniae*. Therefore, drosocin analogs with trans-4-hydroxy-L-proline positions were found

to be four- to eight-time more stable in mouse serum than the unmodified analogs [191].

Furthermore, not only the linear and free chain terminations but also the presence of multiple cleavage sites can be readily recognized by the host and bacterial proteases, which can promptly degrade AMPs into inactive fragments. However, after chemical modifications integrated to improve molecular strength against hydrolysis a new structure of AMP is achieved, so it is fundamental to analyze the new AMP characteristics, to avoid, among other issues, bioaccumulation and toxicity [192]. Likewise, the eventual risk of immunogenic effects must be considered [189, 190].

Hence, researchers have to consider structural and functional information such as the study of secondary structure, amino acid composition, length, cationicity, hydrophobicity, and amphipathicity to better obtain a suitable drug candidate with improved stability *in vivo*.

The chemical modifications play thus a crucial role in the improvement of both the pharmacological activity and biocompatibility, as well as contributing to the chemical stability of the AMP molecules [193–196]. Practically, the main chemical modifications can be included directly during the solid-phase peptide synthesis technique, by which the linear peptide precursor can be assembled from the C-terminal residue, which is linked to the solid resin support. To prevent unwanted couplings during synthesis, a well-known approach considers the use of 9-fluorenylmethyloxycarbonyl (Fmoc) protecting groups. After purification, the obtained linear peptide is let to fold and to cyclize in an appropriate alkaline buffer [197]. Hence, an extra rigidity of the peptide structure may contribute to protract the elimination half-life [198–200].

Including also a broader consideration of the sources, a summary of the most frequent AMP modifications is reported below.

D-Amino acid substitutions

AMPs can be modified mainly by introducing D-amino acids (DAA) not only in specific regions but also involving all the wild-type sequences. DAA contributes to the partial or the total reversion of the stereochemistry, contributing to enhancing the stability of the peptide against stereospecific proteases [195].

Several studies explored the effect of amino acid substitutions with specific D-amino acids on AMPs activity. To improve the proteolytic resistance, two peptides isolated from the venom of the social wasp *Polybia paulista*, i.e. polybia-MPI and polybia-CP [201], were both partially and totally substituted with DAA. As reported by Zhao and co-workers, the selected AMP was specifically modified with two strategies: (i) by realizing an MPI-analog with D-lysine

(D-Lys-MPI); by obtaining (ii) the D-enantiomer of polybia-MPI (D-MPI). Subsequently, the properties of both D-MPI and D-Lys-MPI were compared [202]. Hence, the authors found that the D-Lys-MPI gained extra stability, together with a loss of the antimicrobial activity due to the impairment of the α -helix. On the contrary, to retain the antimicrobial effect as well as to improve molecular stability, the D-MPI demonstrated stable when tested with trypsin and chymotrypsin, and its antimicrobial activity revealed like the wild-type compound (i.e. L-MPI). Against all tested bacteria, the minimal inhibitory concentrations (MIC) of the D-MPI demonstrated greater than the D-Lys-MPI, with an auspicious antimicrobial effect towards both *P. aeruginosa* (MIC 64 μ M), and *S. aureus* (MIC 16 μ M). Instead, the minimal bactericidal concentration (MBC) was found twofold and fourfold higher, respectively, than MIC values. Taken together, these results have contributed to confirming that the effect of polybia-MPI did not require stereospecific interactions. Therefore, the D-substitution may offer a chemical strategy to improve the stability of the selected APM against protease degradation [202].

The partial and total substitution of DAA in the wild-type sequence was also reported by Jia and co-workers using the polybia-CP compound. Their results demonstrated that both the polybia-CP D-analog, as well as the D-Lys analog, indicated comparable antibacterial activity than the polybia-CP wild-type compound. Furthermore, both MIC and MBC values were not disturbed by each substitution strategy, even though a molecular stability improvement against the enzymatic degradation was observed. Moreover, the D-analog of polybia-CP (D-CP) demonstrated stability to both trypsin and chymotrypsin proteolytic effect, whereas D-Lys analog revealed resistance to trypsin only [203].

However, although preventing protease degradation, partial or total substitution with D-amino amino acids has been demonstrated to be very costly [204].

N-terminal modifications

The half-life in plasma of a peptide seems related to the typology of the N-terminus residue. N-terminal residues such as Alanine (Ala), Gly, Methionine (Met), Serine (Ser), Threonine (Thr), or Valine (Val) confer to peptides longer half-life. On the contrary, peptides with shorter half-life have been characterized by Arginine (Arg), Aspartate (Asp), Leucine (Leu), Lysine (Lys), or Phenylalanine (Phe) linked at the N-terminus. Likewise, if peptide domains report an enrichment in residues such as Glutamine (Gln), Proline (Pro), Ser, and Thr they are more susceptible to enzymatic degradation [188]. Hence, to block the aminopeptidase action as well as to increase the proteolytic degradation stability of peptides intended for therapeutic use, a common

strategy to overpass enzymatic degradation is the acetylation of the N-terminus [195].

Bacteria and eukaryotes can exhibit the N-alkylation of amino acids. For instance, peptides with N-methyl amino acid display an improved resistance against proteolytic degradation, but also a better ability to permeate membranes than their original peptides. N-methyl-amino acids also characterize drugs like cyclosporin A [205]. This cyclic peptide has seven N-methyl-amino acids, and it displays potent bioactivity, and good oral bioavailability [206]. Concerning N-alkylation, Liu and co-workers modified the wild-type sequence of the peptide anoplin in two main ways. They chemically modified the anoplin, the smallest linear α -helical AMP isolated from the venom sac of solitary spider wasps *Anoplius samarensis*, with N-methyl amino acids selecting specific positions, as well as introducing fatty acids with various chain lengths. Initially, the authors underwent anoplin with single and multiple N-methyl amino acid substitutions to determine the cleave sites which are recognized by trypsin and chymotrypsin and, therefore, to confer resistance against peptide degradation. Hence, N-methyl amino acids replaced specific residues of Leu, Ile, Lys, and Arg, identified to be sensitive to enzymatic cleavage. The authors found that the steric burden of the N-methyl amino group influenced the molecule conformation and, consequently, the interaction with peptidases. Further evaluations were also conducted to explain whether the antimicrobial activity was affected, as well. For instance, analogs with single and multiple N-methyl amino acid substitutions demonstrated lacking antimicrobial effect against American Type Culture Collection (ATCC) strains of *E. coli*, *S. aureus*, *B. subtilis*, *P. aeruginosa*, and *K. pneumoniae*. The depletion of antimicrobial activity was influenced by the positions or by the number of amino acids replaced with N-methylation. In addition, further explanations were connected to the decrease of the conformational flexibility and to the removal of potential hydrogen bonding that can occur at specific positions. Nonetheless, a slight increase of MIC values when the N-methyl amino acid replacements pertained to the proximity of the C- or N-terminals was also observed [206]. Subsequently, to enhance the antimicrobial activity, the analogs that showed the high proteolytic stability were chosen for the second chemical adjustment. Hence, the N-terminal was modified by introducing fatty acids with chain lengths ranging from C8 to C14. The antimicrobial activity of the N-methylated lipopeptides with C12/C14 exhibited greater antimicrobial effects against both Gram-negative and Gram-positive bacteria, selecting the C12 compound as the most promising analog. However, the cytotoxicity of N-methylated and C12-analog was also observed, due to the non-selectivity membrane affinity of lipid, inducing hemolytic activity [206].

Zhong and colleagues reported a series of new monomer and dimer peptides that they synthesized by conjugating

fatty acids at the N-terminus. The selected AMP was a partial DAA substituted analogue of anoplin. Along with the dimerization of the AMP, the authors showed an alternative method to improve both the anoplin antimicrobial activity and the stability. Moreover, the authors found the lowest MIC when the chain length ranged between C8 and C12. Specifically, a fatty acid chain of C10 showed the lowest MIC towards *P. aeruginosa* ATCC 27853. Against both *S. aureus* species, i.e. ATCC 25923 and MRSA 936, they found a MIC of 8 μ M. The dimerization of the helix brought greater MICs for almost all tested species of Gram-negative bacteria. Focusing also on *S. aureus* biofilm inhibition percentage, the authors reported a high rate using a concentration of 2xMIC of peptides characterized by chain lengths of C8, C10, and C12. The biofilm inhibition was then found comparable to unmodified anoplin and polymyxin taken as controls. Considering *P. aeruginosa* species, the authors also found a better rate percentage of inhibition using peptides with the fatty acids chain lengths of C10, and C12, both taken at 2xMIC concentration, whereas using dimers, the effect of inhibition was not significant. The authors also suggested that, in combination with conventional antibiotics, the modified AMPs with a fatty acid chain, along with dimer constitution from modified peptides, may open the way to synergism towards the inhibition of the biofilm formation [207].

Cyclization and dimerization

Molecular stability represents a crucial requirement for AMPs to be used as new active pharmaceutical ingredients. Several disulfide-rich peptide families, such as plant cyclotides [208] or primate-related θ -defensin [209] display Cys-stabilized structures with a well-defined three-dimensional motif. Focusing on AMP modifications, it is possible to realize the cyclization by three main post-translational methods, i.e. by peptide, lactam, or disulfide bonds. Therefore, by chemical or biological approaches, it is possible to restrict the conformational bend of the peptide structure by introducing some conformational constraints. The modification of the wild-type sequence by cyclization confers rigidity to peptide chains, so the new structural achievement exhibits a minor attitude to be hydrolyzed by proteases [195, 196, 210]. Nonetheless, chemical modifications might also affect the pharmacological effect.

The bioactive conformation of drosocin, a 19-residue proline-rich inducible antibacterial peptide from *D. melanogaster* [147, 211], and apidaecin, a 17-residue from *Apis mellifera* [104] were studied by Gobbo and co-workers. They showed that only the large cyclic dimer of apidaecin moderately retained the antimicrobial activity and the obtained bending of the peptide chain was then not a structural

element characteristic of the bioactive conformation of drosocin and apidaecin [148].

To be provided with more information about cyclic and circular peptides, it is possible to consult an open-access database <http://www.cybase.org.au/> [212]. Furthermore, most of the approved antimicrobial peptides by the FDA are cyclic structures (e.g. vancomycin, oritavancin, dalbavancin, and telavancin). Due to their higher stability in vivo than that of their linear equivalents, molecular stability represents, therefore, a key factor in reaching the approval [213].

Insect AMPs to counteract the bacterial biofilm issue

The AMPs used against biofilm act in different way such as (i) the inhibition of planktonic bacteria to adhere to the substrate and the increase the expression regarding motility genes check, (ii) the downregulation of the extracellular matrix synthesis, and (iii) direct bacterial killing. However, most AMP databases consider the AMP antibacterial activity against planktonic bacteria. To fill this gap, Di Luca and co-workers created a database (<http://baamps.it/>) to address the organization of the AMP antibiofilm activity and to support the antibiofilm study. The antibiofilm field can be considered an emerging research area as reported by Home and Di Luca [214, 215].

Several AMPs, particularly insect cecropins, show the ability to counteract biofilm formation. As reported above, biofilms are a group of microbial cells irreversibly associated to a surface and enclosed in a self-produced matrix, which consists of DNA, polysaccharides, and proteins. It constitutes a barrier that protects bacteria from a variety of chemical, physical, and biological stresses [216]. Biofilms can grow on several surfaces including human skin, teeth, as well as bone and urinary tracts implants, valves, and other artificial implants. When bacteria switch to the biofilm mode of growth, the biomaterial-associated infections are difficult to treat with conventional antibiotic therapies [217]. A crucial problem connected to infections causing respiratory illness is also represented by biofilm development within the lung.

Several studies are reported on insect AMP with antibiofilm effect. Hwang and co-workers focused on a defensin-like peptide derived from the dung beetle *Copris tripartitus*. The authors investigated the antimicrobial and antibiofilm activities of a *C. tripartitus*-derived AMP, the coprisin, alone, or in combination with conventional antibiotics. The antibacterial susceptibility testing was conducted against Gram-positive and Gram-negative bacterial strains including *E. faecium* ATCC 19434, *S. aureus* ATCC 25923, *S. mutans* KCTC 3065 from the Korean Collection for Type Cultures (KCTC), two *E. coli* strains, i.e. O-157 ATCC 25922, and ATCC 43895 respectively, and *P. aeruginosa* ATCC 27853. Using the Tissue Culture

Plate Method, the antibiofilm activity with a pre-formed biofilm method was tested. A high percentage of biofilm inhibition reported as mean \pm SD was found when coprisin was tested against Gram-negative species, ranging between $80.4 \pm 4.4\%$ and $86.2 \pm 3.3\%$. The combination of coprisin and ampicillin reporting the highest percentage of biofilm inhibition against *E. coli* O-157 and *P. aeruginosa*, i.e. $90.1 \pm 2.9\%$ and $91.7 \pm 2.5\%$, respectively [218].

Chemical synthesized Pro9-3 and Pro9-3D defensins, originated from beetle *Protaetia brevitarsis*, inhibited biofilm formation in *E. coli* and *A. baumannii* in a concentration-dependent manner. Pro9-3 peptide was also modified to increase cationicity and resistance to protease activity, adding Arg to the N-terminus: this modification highly increases the ability to inhibit biofilm formation and to disrupt the mature biofilms, also of MDR strains (MDREC 1229 and MDRA 12010) [219].

Uropathogenic *E. coli* biofilms are a typical complication of urinary tract infections that contribute to chronicize the disease. Insect AMP cecropin A from *G. mellonella* is able to disrupt planktonic and sessile biofilm cells, alone or combined with the antibiotic nalidixic acid. This finding clearly highlights the high potential of synergistic action between AMPs and classical antibiotics to treat in vivo infection [220].

Very interesting studies showed the antibiofilm performances of a complex mixture of defensin, cecropin, diptericin, proline-rich, and domesticin-like peptides, induced by *C. vicina* immune response after *E. coli* M17 strain infection. In nature, *C. vicina* lives in extremely contaminated areas, rich in bacteria, so this insect innately produces a lot of AMPs simultaneously. The AMP complex displays strong biofilm-breaking activity against human antibiotic-resistant pathogens, such as different strains of *E. coli*, *S. aureus*, *P. aeruginosa*, *K. pneumoniae*, and *A. baumannii*. The inhibition degree is strictly related to specific bacterial strains. The possible synergy between AMP mixture and many common antibiotics (meropenem, amikacin, kanamycin, ampicillin, vancomycin, cefotaxime, clindamycin, erythromycin, chloramphenicol, oxacillin, tetracycline, ciprofloxacin, gentamicin, and polymyxin B) was also evaluated, demonstrating different positive level of interaction in all bacteria, except polymyxin B in *E. coli*. Moreover, this AMP cocktail does not have toxicity to human cells [221, 222].

AMPs in ongoing clinical trials

Currently, there are still no insect-derived AMP products derived from insects on the biopharmaceutical market [223]. Surely, the insect AMPs may be exploited as an

alternative to conventional antibiotics, or a support to synergize their activity.

Although many insect AMPs are synthetized and tested against bacterial strains, few clinical studies are achieved, especially concerning anticancer activity. For example, two peptides from *Oryctes rhinoceros*, the rhinoceros beetle, were successfully tested: the defensin ALYLAIRR-NH₂ strongly inhibited MRSA in vivo and in vitro; the D-peptide B, an anticancer peptide, disrupted mouse myeloma cells in vitro with no effects on normal leukocytes [224, 225]. Another AMP molecule, Pierisin-1, AMP from *Pieris rapae*, shows anticancer activity, inducing apoptosis and cytotoxicity in some mammalian cancer cell lines (lung, renal, colorectal, bladder, cervical, and liver) by mono-ADP-ribosylation of DNA [226, 227].

Currently, the clinical use of insect AMPs is really limited because of lacking information concerning bioavailability, instability to proteases, toxicity and side effects [228].

Conclusions

Insects lack adaptive immunity and base their survival on the production of broad-spectrum AMPs which allow them to create powerful defense mechanisms to counteract infections. In fact, due to the variety of substrates they eat and to the environments in which they live, insects have developed a great variety of responses within the innate immunity. For this reason, with over 1 million described species, they constitute an almost inexhaustible source of biologically active compounds. Several bacteria developed multidrug resistance to modern antibiotics, thus there is a great interest in finding and developing new antimicrobial drugs. Most insect AMPs are cationic due to the presence of basic residues in their amino acid sequences. Thus, they are positively charged at physiological pH, and the positive net charge facilitates their binding to negatively charged microbial surfaces through electrostatic interactions. Thanks to their antibacterial activity and to their ability to be active against fungi, viruses and some cancer cell lines, insect AMPs attract great attention in the biomedical field. In addition, it has been demonstrated that some peptides exhibit an antibiofilm activity and this characteristic makes them good candidates for the use on medical devices to drastically reduce the formation of microbial colonies and biofilm development. The balance of several advantageous parameters from innovative drug delivery systems, along with further chemical stability may confer to AMP-based therapies a suitable potency and biocompatibility. Therefore, considering their broad-spectrum antimicrobial activity, AMPs represent interesting candidates

for therapeutic use and will certainly be the object of further research in the future. Moreover, the possibility to use the arsenal of insect AMPs will constitute a great advantage as the management of insects in the laboratory and at higher levels has many advantages: low environmental impact, significantly reduced research cost and time, thanks to the simplicity in breeding them and the high rate of reproduction. In addition, insects breeding overcome ethical problems.

Author contributions Conceptualization: PF; writing—original draft preparation: PF, MDM, AM, RS, and CS; writing—review and editing: MDM, AM, RS, CS, AS, DL, HV, and PF; supervision: PF.

Funding Open access funding provided by Università degli Studi della Basilicata within the CRUI-CARE Agreement. This research was supported by the Italian Ministry of Instruction, University and Research (MIUR) within the frameworks of the project PRIN 2017 (protocol Prot. 2017AHTCK7).

Compliance with ethical standards

Conflicts of interest The authors declare that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Martens E, Demain AL (2017) The antibiotic resistance crisis, with a focus on the United States. *J Antimicrob Agents Chemother*. <https://doi.org/10.1038/ja.2017.30> ((Tokyo))
2. Payne DJ, Gwynn MN, Holmes DJ, Pommerville DL (2007) Drugs for bad bugs: confronting the challenges of antibacterial discovery. *Nat Rev Drug Discov* 6:29–40
3. Tommasi R, Brown DG, Walkup GK, Manchester JI, Miller AA (2015) ESKAPEing the labyrinth of antibacterial discovery. *Nat Rev Drug Discov* 14:529–542
4. Beceiro A, Tomás M, Bou G (2013) Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world? *Clin Microbiol Rev*. <https://doi.org/10.1128/CMR.00059-12>
5. Ghosh A, Saran N, Saha S (2020) Survey of drug resistance associated gene mutations in *Mycobacterium tuberculosis*, ESKAPE and other bacterial species. *Sci Rep* 10:1–11. <https://doi.org/10.1038/s41598-020-65766-8>

6. WHO (2017) Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. <https://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/>. Accessed 13 Feb 2021
7. Neshani A, Sedighian H, Mirhosseini SA, Ghazvini K, Zare H, Jahangiri A (2020) Antimicrobial peptides as a promising treatment option against *Acinetobacter baumannii* infections. *Microb Pathog*. <https://doi.org/10.1016/j.micpath.2020.104238>
8. De Soyza A, Aksamit T (2016) Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. *Expert Opin Orphan Drugs* 4:875–884
9. McShane PJ, Weers JG, Tarara TE, Haynes A, Durbha P, Miller DP, Mundry T, Operschall E, Elborn JS (2018) Ciprofloxacin dry powder for inhalation (ciprofloxacin DPI): technical design and features of an efficient drug-device combination. *Pulm Pharmacol Ther* 50:72–79
10. Varga JJ, Barbier M, Mulet X, Bielecki P, Bartell JA, Owings JP, Martinez-Ramos I, Hittle LE, Davis MR, Damron FH (2015) Genotypic and phenotypic analyses of a *Pseudomonas aeruginosa* chronic bronchiectasis isolate reveal differences from cystic fibrosis and laboratory strains. *BMC Genom* 16:883
11. Gollan B, Grabe G, Michaux C, Helaine S (2019) Bacterial persisters and infection: past, present, and progressing. *Annu Rev Microbiol* 73:359–385. <https://doi.org/10.1146/annurev-micro-020518-115650>
12. Bush K, Page MGP (2017) What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles. *J Pharmacokinet Pharmacodyn* 44:113–132. <https://doi.org/10.1007/s10928-017-9506-4>
13. Dian Permana A, Mir M, Utomo E, Donnelly RF (2020) Bacterially sensitive nanoparticle-based dissolving microneedles of doxycycline for enhanced treatment of bacterial biofilm skin infection: a proof of concept study. *Int J Pharm*. <https://doi.org/10.1016/j.ijpharm.2020.119220>
14. Haisma EM, Göblyös A, Ravensbergen B, Adriaans AE, Cord-funke RA, Schrumpf J, Limpens RWAL, Schimmel KJM, Den Hartigh J, Hiemstra PS, Drijfhout JW, El Ghalbzouri A, Nibbering PH (2016) Antimicrobial peptide P60.4Ac-containing creams and gel for eradication of methicillin-resistant *Staphylococcus aureus* from cultured skin and airway epithelial surfaces. *Antimicrob Agent Chemother* 60:4063–4072. <https://doi.org/10.1128/AAC.03001-15>
15. Martínez LC, Vadyvaloo V (2014) Mechanisms of post-transcriptional gene regulation in bacterial biofilms. *Front Cell Infect Microbiol* 4:38. <https://doi.org/10.3389/fcimb.2014.00038>
16. Sharma D, Choudhary M, Vashist J, Shrivastava R, Bisht GS (2019) Cationic antimicrobial peptide and its poly-N-substituted glycine congener: antibacterial and antbiofilm potential against *A. baumannii*. *Biochem Biophys Res Commun* 518:472–478. <https://doi.org/10.1016/j.bbrc.2019.08.062>
17. Bjarnsholt T, Alhede M, Alhede M, Eickhardt-Sørensen SR, Moser C, Kühl M, Jensen PØ, Høiby N (2013) The *in vivo* biofilm. *Trends Microbiol* 21:466–474. <https://doi.org/10.1016/j.tim.2013.06.002>
18. Bjarnsholt T, Ciofu O, Molin S, Givskov M, Høiby N (2013) Applying insights from biofilm biology to drug development-can a new approach be developed? *Nat Rev Drug Discov* 12:791–808. <https://doi.org/10.1038/nrd4000>
19. Lindsay D, Von Holy A (2006) Bacterial biofilms within the clinical setting: what healthcare professionals should know. *J Hosp Infect* 64:313–325
20. Moskowitz SM, Foster JM, Emerson J, Burns JL (2004) Clinically feasible biofilm susceptibility assay for isolates of *Pseudomonas aeruginosa* from patients with cystic fibrosis. *J Clin Microbiol* 42:1915–1922. <https://doi.org/10.1128/JCM.42.5.1915-1922.2004>
21. Visaggio D, Pasqua M, Bonchi C, Kaever V, Visca P, Imperi F (2015) Cell aggregation promotes pyoverdine-dependent iron uptake and virulence in *Pseudomonas aeruginosa*. *Front Microbiol* 6:902. <https://doi.org/10.3389/fmicb.2015.00902>
22. Webb JS, Givskov M, Kjelleberg S (2003) Bacterial biofilms: prokaryotic adventures in multicellularity. *Curr Opin Microbiol* 6:578–585
23. Wei Q, Ma LZ (2013) Biofilm matrix and its regulation in *Pseudomonas aeruginosa*. *Int J Mol Sci* 14:20983–21005
24. Jimenez PN, Koch G, Thompson JA, Xavier KB, Cool RH, Quax WJ (2012) The multiple signaling systems regulating virulence in *Pseudomonas aeruginosa*. *Microbiol Mol Biol Rev* 76:46–65
25. Aslam S, Darouiche RO (2011) Role of antibiofilm-antimicrobial agents in controlling device-related infections. *Int J Artif Organs* 34:752–758. <https://doi.org/10.5301/ijao.5000024>
26. Flume PA, VanDevanter DR (2015) Clinical applications of pulmonary delivery of antibiotics. *Adv Drug Deliv Rev* 85:1–6
27. Majik MS, Parvatkar PT (2014) Next generation biofilm inhibitors for *Pseudomonas aeruginosa*: synthesis and rational design approaches. *Curr Top Med Chem* 14:81–109
28. Valedo A, Cabanes D, Sousa S (2016) Bacterial toxins as pathogen weapons against phagocytes. *Front Microbiol*. <https://doi.org/10.3389/fmicb.2016.00042>
29. Lam PL, Lee KK, Wong RSM, Cheng GYM, Bian ZX, Chui CH, Gambari R (2018) Recent advances on topical antimicrobials for skin and soft tissue infections and their safety concerns. *Crit Rev Microbiol* 44:40–78. <https://doi.org/10.1080/104041X.2017.1313811>
30. Moir DT, Opperman TJ, Butler MM, Bowlin TL (2012) New classes of antibiotics. *Curr Opin Pharmacol* 12:535–544
31. Wright GD (2017) Antibiotic adjuvants: rescuing antibiotics from resistance. *Trends Microbiol* 24:862–871. <https://doi.org/10.1016/j.tim.2016.06.009>
32. Bradshaw JP (2003) Cationic antimicrobial peptides. *BioDrugs* 17(4):233–240
33. Hoskin DW, Ramamoorthy A (2008) Studies on anticancer activities of antimicrobial peptides. *Biochimica et Biophysica Acta (BBA)-Biomembranes* 1778(2):357–375
34. Schweizer F (2009) Cationic amphiphilic peptides with cancer-selective toxicity. *Eur J Pharmacol* 625(1–3):190–194
35. Guzmán-Rodríguez JJ, Ochoa-Zarzosa A, López-Gómez R, & López-Meza JE (2015) Plant antimicrobial peptides as potential anticancer agents. *BioMed research international*, 2015.
36. Hillyer JF (2016) Insect immunology and hematopoiesis. *Dev Comp Immunol* 58:102–118
37. Vallet-Gely I, Lemaitre B, Boccard F (2008) Bacterial strategies to overcome insect defences. *Nat Rev Microbiol*. <https://doi.org/10.1038/nrmicro1870>
38. Kanost MR, Jiang H, Yu XQ (2004) Innate immune responses of a lepidopteran insect, *Manduca sexta*. *Immunol Rev*. <https://doi.org/10.1111/j.0105-2896.2004.0121>
39. Lemaitre B, Hoffmann J (2007) The Host Defense of *Drosophila melanogaster*. *Annu Rev Immunol* 25:697–743. <https://doi.org/10.1146/annurev.immunol.25.022106.141615>
40. Tsakas S, Marmaras VJ (2010) Insect immunity and its signalling: an overview. *Invertebr Surviv J* 7:228–238
41. Lu HL, Leger RS (2016) Insect immunity to *Entomopathogenic fungi*. *Adv Genet* 94:251–285
42. Hultmark D, Steiner H, Rasmussen T, Boman HG (1980) Insect immunity. Purification and properties of three inducible bactericidal proteins from hemolymph of immunized pupae of *Hyalophora cecropia*. *Eur J Biochem* 106:7–16. <https://doi.org/10.1111/j.1432-1033.1980.tb05991>

43. Ursic-Bedoya R, Buchhop J, Joy JB, Durvasula R, Lowenberger C (2011) Prolixicin: a novel antimicrobial peptide isolated from *Rhodnius prolixus* with differential activity against bacteria and *Trypanosoma cruzi*. *Insect Mol Biol* 20:775–786. <https://doi.org/10.1111/j.1365-2583.2011.01107>
44. Vilcinskas A (2011) Anti-infective therapeutics from the Lepidopteran model host *Galleria mellonella*. *Curr Pharm Des* 17:1240–1245
45. Vonkavaara M, Pavel STI, Hölzl K, Nordfelth R, Sjöstedt A, Stöven S (2013) Francisella is sensitive to insect antimicrobial peptides. *J Innate Immun* 5:50–59. <https://doi.org/10.1159/000342468>
46. Kruse T, Kristensen HH (2008) Using antimicrobial host defense peptides as anti-infective and immunomodulatory agents. *Expert Rev Anti Infect Ther*. <https://doi.org/10.1586/14787210.6.6.887>
47. Chernysh S, Kim SI, Bekker G, Pleskach VA, Filatova NA, Anikin VB, Platonov VG, Bulet P (2002) Antiviral and antitumor peptides from insects. *Proc Natl Acad Sci U S A* 99:12628–12632. <https://doi.org/10.1073/pnas.192301899>
48. Imamura M, Wada S, Ueda K, Saito A, Koizumi N, Iwahana H, Sato R (2009) Multipeptide precursor structure of acaloleptin A isoforms, antibacterial peptides from the Udo longicorn beetle, *Acalolepta luxuriosa*. *Dev Comp Immunol* 33:1120–1127. <https://doi.org/10.1016/j.dci.2009.06.004>
49. Langen G, Imani J, Altincicek B, Kieseritzky G, Kogel KH, Vilcinskas A (2006) Transgenic expression of gallerimycin, a novel antifungal insect defensin from the greater wax moth *Galleria mellonella*, confers resistance to pathogenic fungi in tobacco. *Biol Chem* 387:549–557. <https://doi.org/10.1515/BC.2006.071>
50. Pöppel AK, Koch A, Kogel KH, Vogel H, Kollewe C, Wiesner J, Vilcinskas A (2014) Lucimycin, an antifungal peptide from the therapeutic maggot of the common green bottle fly *Lucilia sericata*. *Biol Chem* 395:649–656. <https://doi.org/10.1515/hsz-2013-0263>
51. Hancock REW, Sahl HG (2006) Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. *Nat Biotechnol*. <https://doi.org/10.1038/nbt1267>
52. Lakshmaiah Narayana J, Chen J-Y (2015) Antimicrobial peptides: possible anti-infective agents. *Peptides* 72:88–94. <https://doi.org/10.1016/j.peptides.2015.05.012>
53. Yi H-Y, Chowdhury M, Huang Y-D, Yu X-Q (2014) Insect antimicrobial peptides and their applications. *Appl Microbiol Biotechnol* 98:5807–5822
54. Liu D, Liu J, Li J, Xia L, Yang J, Sun S, Ma J, Zhang F (2017) A potential food biopreservative, CecXJ-37N, non-covalently intercalates into the nucleotides of bacterial genomic DNA beyond membrane attack. *Food Chem* 217:576–584. <https://doi.org/10.1016/j.foodchem.2016.09.033>
55. Romoli O, Mukherjee S, Mohid SA, Dutta A, Montali A, Franzolin E, Brady D, Zito F, Bergantino E, Rampazzo C, Tettamanti G, Bhunia A, Sandrelli F (2019) Enhanced silkworm Cecropin B antimicrobial activity against *Pseudomonas aeruginosa* from single amino acid variation. *ACS Infect Dis* 5:1200–1213. <https://doi.org/10.1021/acsinfecdis.9b00042>
56. Cole MA, Scott TF, Mello CM (2016) Bactericidal hydrogels via surface functionalization with Cecropin A. *ACS Biomater Sci Eng* 2:1894–1904. <https://doi.org/10.1021/acsbiomaterials.6b00266>
57. Querido MM, Felgueiras HP, Rai A, Costa F, Monteiro C, Borges I, Oliveira D, Ferreira L, Martins MCL (2018) Cecropin-melittin functionalized polyurethane surfaces prevent *Staphylococcus epidermidis* adhesion without inducing platelet adhesion and activation. *Adv Mater Interfaces* 5:1801390. <https://doi.org/10.1002/admi.201801390>
58. Coca M, Peñas G, Gómez J, Campo S, Bortolotti C, Messeguer J, Segundo BS (2006) Enhanced resistance to the rice blast fungus *Magnaporthe grisea* conferred by expression of a cecropin A gene in transgenic rice. *Planta* 223:392–406. <https://doi.org/10.1007/s00425-005-0069-z>
59. Jan PS, Huang HY, Chen HM (2010) Expression of a synthesized gene encoding cationic peptide cecropin B in transgenic tomato plants protects against bacterial diseases. *Appl Environ Microbiol* 76:769–775. <https://doi.org/10.1128/AEM.00698-09>
60. Mitsuhashi I, Matsufuru H, Ohshima M, Kaku H, Nakajima Y, Murai N, Natori S, Ohashi Y (2000) Induced expression of sarcotoxin IA enhanced host resistance against both bacterial and fungal pathogens in transgenic tobacco. *Mol Plant-Microbe Interact* 13:860–868. <https://doi.org/10.1094/MPMI.2000.13.8.860>
61. Cooper D, Eleftherianos I (2017) Memory and specificity in the insect immune system: current perspectives and future challenges. *Front Immunol* 8:539. <https://doi.org/10.3389/fimmu.2017.00539>
62. Pesch Y, Riedel D, Patil K, Loch G, Behr M (2016) Chitinases and imaginal disc growth factors organize the extracellular matrix formation at barrier tissues in insects. *Sci Rep* 6:18340. <https://doi.org/10.1038/srep18340>
63. Sheehan G, Farrell G, Kavanagh K (2020) Immune priming: the secret weapon of the insect world. *Virulence* 11:238–246. <https://doi.org/10.1080/21505594.2020.1731137>
64. Strand MR (2008) The insect cellular immune response. *Insect Sci*. <https://doi.org/10.1111/j.1744-7917.2008.00183>
65. Tang H (2009) Regulation and function of the melanization reaction in *Drosophila*. *Fly* 3:105–111
66. Nakhleh J, Moussawi LE, Osta MA (2017) Chapter three—the melanization response in Insect Immunity. *Advances in Insect Physiology* 52:83–109
67. Cerenius L, Lee BL, Söderhäll K (2008) The proPo-system: pros and cons for its role in invertebrate immunity. *Trends Immunol* 29:263–271
68. Ling E, Yu XQ (2005) Prophenoloxidase binds to the surface of hemocytes and is involved in hemocyte melanization in *Manduca sexta*. *Insect Biochem Mol Biol* 35:1356–1366
69. Pascale M, Laurino S, Vogel H, Grimaldi A, Monné M, Riviello L, Tettamanti G, Falabella P (2014) The Lepidopteran endoribonuclease-U domain protein P102 displays dramatically reduced enzymatic activity and forms functional amyloids. *Dev Comp Immunol* 47(1):129–139
70. Falabella P, Riviello L, Pascale M, Lelio ID, Tettamanti G, Grimaldi A, Iannone C, Monti M, Pucci P, Tamburro AM, Deeguileor M, Gigliotti S, Pennacchio F (2012) Functional amyloids in insect immune response. *Insect Biochem Mol Biol* 42:203–211. <https://doi.org/10.1016/j.ibmb.2011.11.011>
71. Nappi AJ, Christensen BM (2005) Melanogenesis and associated cytotoxic reactions: applications to insect innate immunity. *Insect Biochem Mol Biol* 35:443–459. <https://doi.org/10.1016/j.ibmb.2005.01.014>
72. Lavine MD, Strand MR (2002) Insect hemocytes and their role in immunity. *Insect Biochem Mol Biol* 32:1295–1309. [https://doi.org/10.1016/S0965-1748\(02\)00092-9](https://doi.org/10.1016/S0965-1748(02)00092-9)
73. Satyavathi VV, Minz A, Nagaraju J (2014) Nodulation: an unexplored cellular defense mechanism in insects. *Cell Signal* 26:1753–1763. <https://doi.org/10.1016/j.cellsig.2014.02.024>
74. Williams MJ (2007) *Drosophila hemopoiesis* and cellular immunity. *J Immunol* 178:4711–4716
75. Janeway CA Jr, Medzhitov R (2002) Innate immune recognition. *Annu Rev Immunol* 20:197–216
76. Iwanaga S, Lee BL (2005) Recent advances in the innate immunity of invertebrate animals. *J Biochem Mol Biol* 38:128
77. Dossey AT (2010) Insects and their chemical weaponry: new potential for drug discovery. *Nat Prod Rep* 27:1737–1757
78. Brogden KA (2005) Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? *Nat Rev Microbiol* 3:238–250

79. Steiner H, Hultmark D, Engström Å, Bennich H, Boman HG (1981) Sequence and specificity of two antibacterial proteins involved in insect immunity. *Nature* 292:246–248. <https://doi.org/10.1038/292246a0>
80. Jin G, Weinberg A (2019) Human antimicrobial peptides and cancer. *Semin Cell Dev Biol* 88:156–162. <https://doi.org/10.1016/j.semcd.2018.04.006>
81. Tonk M, Vilcinskas A, Rahnamaeian M (2016) Insect antimicrobial peptides: potential tools for the prevention of skin cancer. *Appl Microbiol Biotechnol* 100:7397–7405
82. Zasloff M (2002) Antimicrobial peptides of multicellular organisms. *Nature* 415:389–395
83. Vilcinskas A (2013) Evolutionary plasticity of insect immunity. *J Insect Physiol* 59:123–129. <https://doi.org/10.1016/j.jinsphys.2012.08.018>
84. Welcome to the APD3 [WWW Document], n.d. URL <http://aps.unmc.edu/AP/>. Accessed 4 feb 2020
85. Brady D, Grapputo A, Romoli O, Sandrelli F (2019) Insect cecropins, antimicrobial peptides with potential therapeutic applications. *Int J Mol Sci* 20:5862. <https://doi.org/10.3390/ijms20235862>
86. Bulet P, Stocklin R (2005) Insect antimicrobial peptides: structures, properties and gene regulation. *Protein Pept Lett* 12:3–11. <https://doi.org/10.2174/0929866053406011>
87. Makarova O, Johnston P, Rodriguez-Rojas A, El Shazely B, Morales JM, Rolff J (2018) Genomics of experimental adaptation of *Staphylococcus aureus* to a natural combination of insect antimicrobial peptides. *Sci Rep* 8:15359. <https://doi.org/10.1038/s41598-018-33593-7>
88. Gerardo NM, Altincicek B, Anselme C et al (2010) Immunity and other defenses in pea aphids. *Acyrthosiphon pisum* Genome Biol 11:R21. <https://doi.org/10.1186/gb-2010-11-2-r21>
89. Moretta A, Salvia R, Scieuzzo C, Di Somma A, Vogel H, Pucci P, Sgambato A, Wolff M, Falabella P (2020) A bioinformatic study of antimicrobial peptides identified in the black soldier fly (BSF) *Hermetia illucens* (Diptera: Stratiomyidae). *Sci Rep* 10:16875. <https://doi.org/10.1038/s41598-020-74017-9>
90. Erickson MC, Islam M, Sheppard C, Liao J, Doyle MP (2004) Reduction of *Escherichia coli* O157:H7 and *Salmonella enterica* serovar Enteritidis in chicken manure by larvae of the black soldier fly. *J Food Prot* 67:685–690. <https://doi.org/10.4315/0362-028x-67.4.685>
91. Liu Q, Tomberlin JK, Brady JA, Sanford MR, Yu Z (2008) Black soldier fly (Diptera: Stratiomyidae) larvae reduce *Escherichia coli* in dairy manure. *Environ Entomol* 37:1525–1530. [https://doi.org/10.1603/0046-225x-37.6.1525 \(PMID: 19161696\)](https://doi.org/10.1603/0046-225x-37.6.1525)
92. Elhag O, Zhou D, Song Q, Soomro AA, Cai M, Zheng L, Yu Z, Zhang J (2017) Screening, expression, purification and functional characterization of novel antimicrobial peptide genes from *Hermetia ILLUCENS* (L.). *PLoS ONE* 12:e0169582–e0169582. <https://doi.org/10.1371/journal.pone.0169582>
93. Ganz T, Lehrer RI (1995) Defensins. *Pharmacol Ther* 66:191–205. [https://doi.org/10.1016/0163-7258\(94\)00076-F](https://doi.org/10.1016/0163-7258(94)00076-F)
94. Bulet P, Cociancich S, Reuland M, Sauber F, Bischoff R, Hegy G, Van Dorsselaer A, Hetru C, Hoffmann JA (1992) A novel insect defensin mediates the inducible antibacterial activity in larvae of the dragonfly *Aeschna cyanea* (Paleoptera, Odonata). *Eur J Biochem* 209:977–984. <https://doi.org/10.1111/j.1432-1033.1992.tb17371.x>
95. Berman HM, Westbrook J, Zardecki C, Bourne PE (2003) The protein data bank. CRC Press, Protein Struct Determ Anal Appl Drug Discov, p 389
96. Bonmatin J-M, Bonnat J-L, Gallet X, Vovelle F, Ptak M, Reichhart J-M, Hoffmann JA, Keppi E, Legrain M, Achstetter T (1992) Two-dimensional 1 H NMR study of recombinant insect defensin A in water: resonance assignments, secondary structure and global folding. *J Biomol NMR* 2:235–256
97. Cornet B, Bonmatin J-M, Hetru C, Hoffmann JA, Ptak M, Vovelle F (1995) Refined three-dimensional solution structure of insect defensin A. *Structure* 3:435–448. [https://doi.org/10.1016/S0969-2126\(01\)00177-0](https://doi.org/10.1016/S0969-2126(01)00177-0)
98. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE (2004) UCSF Chimera: a visualization system for exploratory research and analysis. *J Comput Chem* 25:1605–1612. <https://doi.org/10.1002/jcc.20084>
99. Bachère E, Destoumieux D, Bulet P (2000) Penaeidins, antimicrobial peptides of shrimp: a comparison with other effectors of innate immunity. *Aquaculture* 191:71–88. [https://doi.org/10.1016/S0044-8486\(00\)00419-1](https://doi.org/10.1016/S0044-8486(00)00419-1)
100. Lee YS, Yun EK, Jang WS, Kim I, Lee JH, Park SY, Ryu KS, Seo SJ, Kim CH, Lee IH (2004) Purification, cDNA cloning and expression of an insect defensin from the great wax moth, *Galleria mellonella*. *Insect Mol. Biol.* 13:65–72. <https://doi.org/10.1111/j.1365-2583.2004.00462.x>
101. Lowenberger C, Bulet P, Charlet M, Hetru C, Hodgeman B, Christensen BM, Hoffmann JA (1995) Insect immunity: isolation of three novel inducible antibacterial defensins from the vector mosquito, *Aedes aegypti*. *Insect Biochem. Mol. Biol.* 25:867–873. [https://doi.org/10.1016/0965-1748\(95\)00043-U](https://doi.org/10.1016/0965-1748(95)00043-U)
102. Boulanger N, Lowenberger C, Volf P, Ursic R, Sigutova L, Sabatier L, Svobodova M, Beverley SM, Späth G, Brun R, Pesson B, Bulet P (2004) Characterization of a defensin from the sand fly *Phlebotomus duboscqi* induced by challenge with bacteria or the protozoan parasite *Leishmania major*. *Infect Immun* 72:7140–7146. <https://doi.org/10.1128/IAI.72.12.7140-7146.2004>
103. Moon HJ, Lee SY, Kurata S, Natori S, Lee BL (1994) Purification and molecular cloning of cDNA for an inducible antibacterial protein from larvae of the coleopteran, *Tenebrio molitor*. *J Biochem* 116:53–58. <https://doi.org/10.1093/oxfordjournals.jbchem.124502>
104. Rees JA, Moniatte M, Bulet P (1997) Novel antibacterial peptides isolated from a European bumblebee, *Bombus pascuorum* (Hymenoptera, apoidea). *Insect Biochem Mol Biol* 27:413–422. [https://doi.org/10.1016/S0965-1748\(97\)00013-1](https://doi.org/10.1016/S0965-1748(97)00013-1)
105. Hwang J-S, Lee J, Kim Y-J, Bang H-S, Yun E-Y, Kim S-R, Suh H-J, Kang B-R, Nam S-H, Jeon J-P, Kim I, Lee DG (2009) Isolation and characterization of a defensin-like peptide (coprisin) from the dung beetle, *Copris tripartitus*. *Int. J. Pept.* 2009:136284. <https://doi.org/10.1155/2009/136284>
106. Ueda K, Imamura M, Saito A, Sato R (2005) Purification and cDNA cloning of an insect defensin from larvae of the longicorn beetle, *Acalolepta luxuriosa*. *Appl Entomol Zool* 40:335–345. <https://doi.org/10.1303/aez.2005.335>
107. Yamauchi H (2001) Two novel insect defensins from larvae of the cupreous chafer, *Anomala cuprea*: purification, amino acid sequences and antibacterial activity. *Insect Biochem Mol Biol* 32:75–84. [https://doi.org/10.1016/S0965-1748\(01\)00082-0](https://doi.org/10.1016/S0965-1748(01)00082-0)
108. Chernysh SI, Gordja NA, Simonenko NP (2000) Diapause and immune response: induction of antimicrobial peptides synthesis in the blowfly, *Calliphora vicina* R-D (Diptera: Calliphoridae). Diapause immune response induction Antimicrob Pept Synth blowfly *Calliphora Vicin* R-D (Diptera Calliphoridae). 3:139–144
109. Fujiwara S, Imai J, Fujiwara M, Yaeshima T, Kawashima T, Kobayashi K (1990) A potent antibacterial protein in royal jelly. Purification and determination of the primary structure of royalisin. *J Biol Chem* 265:11333–11337
110. Cociancich S, Dupont A, Hegy G, Lanot R, Holder F, Hetru C, Hoffmann JA, Bulet P (1994) Novel inducible antibacterial peptides from a hemipteran insect, the sap-sucking bug *Pyrrhocoris apterus*

- apterus. *Biochem J* 300:567–575. <https://doi.org/10.1042/bj3000567>
111. Ishibashi J, Saido-Sakanaka H, Yang J, Sagisaka A, Yamakawa M (1999) Purification, cDNA cloning and modification of a defensin from the coconut rhinoceros beetle, *Oryctes rhinoceros*. *Eur J Biochem* 266:616–623. <https://doi.org/10.1046/j.1432-1327.1999.00906.x>
112. Hultmark D, Engstrom Å, Bennich H, Kapur R, Boman HG (1982) Insect immunity: isolation and structure of Cecropin D and four minor antibacterial components from *Cecropia Pupae*. *Eur J Biochem* 127:207–217. <https://doi.org/10.1111/j.1432-1033.1982.tb06857.x>
113. Moore AJ, Beazley WD, Bibby MC, Devine DA (1996) Antimicrobial activity of cecropins. *J Antimicrob Chemother* 37:1077–1089. <https://doi.org/10.1093/jac/37.6.1077>
114. Andrä J, Berninghausen O, Leippe M (2001) Cecropins, antibacterial peptides from insects and mammals, are potently fungicidal against *Candida albicans*. *Med Microbiol Immunol* 189:169–173. <https://doi.org/10.1007/s430-001-8025-x>
115. Efimova SS, Medvedev RY, Chulkov EG, Schagina LV, Ostrovskaya OS (2018) Regulation of the pore-forming activity of *Cecropin A* by local anesthetics. *Cell tissue biol* 12:331–341. <https://doi.org/10.1134/S1990519X18040028>
116. Lee E, Kim JK, Jeon D, Jeong KW, Shin A, Kim Y (2015) Functional roles of aromatic residues and helices of papilioxin in its antimicrobial and anti-inflammatory activities. *Sci Rep* 5:12048. <https://doi.org/10.1038/srep12048>
117. Yun J, Lee DG (2016) *Cecropin A*-induced apoptosis is regulated by ion balance and glutathione antioxidant system in *Candida albicans*. *IUBMB Life* 68:652–662. <https://doi.org/10.1002/iub.1527>
118. Fu H, Björstad Å, Dahlgren C, Bylund J (2004) A bactericidal *Cecropin-A* peptide with a stabilized α -helical structure possess an increased killing capacity but no proinflammatory activity. *Inflammation* 28:337–343
119. Lu D, Geng T, Hou C, Huang Y, Qin G, Guo X (2016) Bombyx mori *Cecropin A* has a high antifungal activity to entomopathogenic fungus *Beauveria bassiana*. *Gene* 583:29–35. <https://doi.org/10.1016/j.gene.2016.02.045>
120. Srisailam S, Arunkumar AI, Wang W, Yu C, Chen HM (2000) Conformational study of a custom antibacterial peptide cecropin B1: implications of the lytic activity. *Biochim. Biophys Acta (BBA) - Protein Struct Mol Enzymol* 1479:275–285. [https://doi.org/10.1016/S0167-4838\(00\)00008-X](https://doi.org/10.1016/S0167-4838(00)00008-X)
121. Giacometti A, Cirioni O, Ghiselli R, Viticchi C, Moccagiani F, Riva A, Saba V, Scalise G (2001) Effect of mono-dose intraperitoneal cecropins in experimental septic shock. *Crit Care Med* 29:1666–1669
122. Lee E, Shin A, Kim Y (2015) Anti-inflammatory activities of *Cecropin A* and its mechanism of action. *Arch Insect Biochem Physiol* 88:31–44
123. Wang J, Ma K, Ruan M, Wang Y, Li Y, Fu YV, Song Y, Sun H, Wang J (2018) A novel cecropin B-derived peptide with antibacterial and potential anti-inflammatory properties. *PeerJ*. <https://doi.org/10.7717/peerj.5369>
124. Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, Li Y, Wang X, Zhao L (2017) Inflammatory responses and inflammation-associated diseases in organs. *Oncotarget* 9:7204–7218. <https://doi.org/10.18632/oncotarget.23208>
125. Choi CS, Lee IH, Kim E, Kim SI, Kim HR (2000) Antibacterial properties and partial cDNA sequences of cecropin-like antibacterial peptides from the common cutworm, *Spodoptera litura*. *Comp. Biochem Physiol Part C Pharmacol Toxicol Endocrinol* 125:287–297. [https://doi.org/10.1016/S0742-8413\(99\)00117-6](https://doi.org/10.1016/S0742-8413(99)00117-6)
126. Boulanger N, Munks RJL, Hamilton JV, Vovelle F, Brun R, Lehane MJ, Bulet P (2002) Epithelial innate immunity: a novel antimicrobial peptide with antiparasitic activity in the blood-sucking insect *Stomoxys calcitrans*. *J Biol Chem* 277:49921–49926. <https://doi.org/10.1074/jbc.M206296200>
127. Liu X, Guo C, Huang Y, Zhang X, Chen Y (2015) Inhibition of porcine reproductive and respiratory syndrome virus by *Cecropin D* in vitro. *Infect Genet Evol* 34:7–16. <https://doi.org/10.1016/j.meegid.2015.06.021>
128. Kim SR, Hong MY, Park SW, Choi KH, Yun EY, Goo TW, Kang SW, Suh HJ, Kim I, Hwang JS (2010) Characterization and cDNA cloning of a cecropin-like antimicrobial peptide, papilioxin, from the swallowtail butterfly *Papilio xuthus*. *Mol. Cells* 29:419–423. <https://doi.org/10.1007/s10059-010-0050-y>
129. Qu X, Steiner H, Engstrom A, Bennich H, Boman HG (1982) Insect immunity: isolation and structure of Cecropins B and D from pupae of the Chinese oak silk moth, *antheraea pernyi*. *Eur J Biochem* 127:219–224. <https://doi.org/10.1111/j.1432-1033.1982.tb06858.x>
130. Hedengren M, Borge K, Hultmark D (2000) Expression and evolution of the *Drosophila Attacin/Diptericin* gene family. *Biochem Biophys Res Commun* 279:574–581. <https://doi.org/10.1006/bbrc.2000.3988>
131. Hultmark D, Engström A, Andersson K, Steiner H, Bennich H, Boman HG (1983) Insect immunity. Attacins, a family of antibacterial proteins from *Hyalophora cecropia*. *EMBO J* 2:571–576. <https://doi.org/10.1002/j.1460-2075.1983.tb01465.x>
132. Sun S-C, Lindstrom I, Lee J-Y, Faye I (1991) Structure and expression of the attacin genes in *Hyalophora cecropia*. *Eur J Biochem* 196:247–254. <https://doi.org/10.1111/j.1432-1033.1991.tb15811.x>
133. Dushay MS, Roethle JB, Chaverri JM, Dulek DE, Syed SK, Kitami T, Eldon ED (2000) Two attacin antibacterial genes of *Drosophila melanogaster*. *Gene* 246:49–57. [https://doi.org/10.1016/S0378-1119\(00\)00041-X](https://doi.org/10.1016/S0378-1119(00)00041-X)
134. Kang D, Lundström A, Steiner H (1996) Trichoplusia ni attacin A, a differentially displayed insect gene coding for an antibacterial protein. *Gene* 174:245–249. [https://doi.org/10.1016/0378-1119\(96\)00089-3](https://doi.org/10.1016/0378-1119(96)00089-3)
135. Kwon YM, Kim HJ, Kim YI, Kang YJ, Lee IH, Jin BR, Han YS, Cheon HM, Ha NG, Seo SJ (2008) Comparative analysis of two attacin genes from *Hyphantria cunea*. *Comp. Biochem Physiol Part B Biochem Mol Biol* 151:213–220. <https://doi.org/10.1016/j.cbpb.2008.07.002>
136. Ourth DD, Lockey TD, Renis HE (1994) Induction of cecropin-like and attacin-like antibacterial but Not antiviral activity in *Heliothis virescens* larvae. *Biochem Biophys Res Commun* 200:35–44. <https://doi.org/10.1006/bbrc.1994.1410>
137. Rao X-J, Yu X-Q (2010) Lipoteichoic acid and lipopolysaccharide can activate antimicrobial peptide expression in the tobacco hornworm *Manduca sexta*. *Dev Comp Immunol* 34:1119–1128. <https://doi.org/10.1016/j.dci.2010.06.007>
138. Bang K, Park S, Yoo JY, Cho S (2012) Characterization and expression of attacin, an antibacterial protein-encoding gene, from the beet armyworm, *Spodoptera exigua* (Hübner) (Insecta: Lepidoptera: Noctuidae). *Mol Biol Rep* 39:5151–5159. <https://doi.org/10.1007/s11033-011-1311-3>
139. Carlsson A, Engström P, Palva ET, Bennich H (1991) Attacin, an antibacterial protein from *Hyalophora cecropia*, inhibits synthesis of outer membrane proteins in *Escherichia coli* by interfering with omp gene transcription. *Infect Immun* 59:3040–3045
140. Xu X-X, Zhong X, Yi H-Y, Yu X-Q (2012) *Manduca sexta* gloverin binds microbial components and is active against bacteria and fungi. *Dev Comp Immunol* 38:275–284. <https://doi.org/10.1016/j.dci.2012.06.012>
141. Axen A, Carlsson A, Engstrom A, Bennich H (1997) Gloverin, an antibacterial protein from the immune hemolymph of

- hyalophora* pupae. Eur J Biochem 247:614–619. <https://doi.org/10.1111/j.1432-1033.1997.00614.x>
142. Mrinal N, Nagaraju J (2008) Intron loss is associated with gain of function in the evolution of the gloverin family of antibacterial genes in *Bombyx mori*. J Biol Chem 283:23376–23387. <https://doi.org/10.1074/jbc.M801080200>
143. Dimarcq J-L, Keppi E, Dunbar B, Lambert J, Reichhart J-M, Hoffmann D, Rankine SM, Fothergill JE, Hoffmann JA (1988) Insect immunity: purification and characterization of a family of novel inducible antibacterial proteins from immunized larvae of the dipteran *Phormia terraenovae* and complete amino-acid sequence of the predominant member, *diptericin A*. Eur J Biochem 171:17–22. <https://doi.org/10.1111/j.1432-1033.1988.tb13752.x>
144. Ishikawa M, Kubo T, Natori S (1992) Purification and characterization of a diptericin homologue from *Sarcophaga peregrina* (flesh fly). Biochem J 287:573–578. <https://doi.org/10.1042/bj2870573>
145. Reichhart JM, Meister M, Dimarcq JL, Zachary D, Hoffmann D, Ruiz C, Richards G, Hoffmann JA (1992) Insect immunity: developmental and inducible activity of the *Drosophila diptericin* promoter. EMBO J 11:1469–1477
146. Hara S, Yamakawa M (1995) A novel antibacterial peptide family isolated from the silkworm. *Bombyx mori*. Biochem. J. 310(2):651–656. <https://doi.org/10.1042/bj3100651>
147. Bulet P, Dimarcq J-L, Hetru C, Lagueux M, Charlet M, Hegy G, Van Dorsselaer A, Hoffmann JA (1993) A novel inducible antibacterial peptide of *Drosophila* carries an O-glycosylated substitution. J Biol Chem 268:14893–14897
148. Gobbo M, Biondi L, Filira F, Gennaro R, Benincasa M, Scolaro B, Rocchi R (2002) Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues. J Med Chem 45:4494–4504. <https://doi.org/10.1021/jm020861d>
149. Levashina EA, Ohresser S, Bulet P, Reichhart J-M, Hetru C, Hoffmann JA (1995) Metchnikowin, a novel immune-inducible proline-rich peptide from drosophila with antibacterial and antifungal properties. Eur J Biochem 233:694–700. https://doi.org/10.1111/j.1432-1033.1995.694_2.x
150. Moghaddam MRB, Gross T, Becker A, Vilcinskas A, Rahnamaeian M (2017) The selective antifungal activity of *Drosophila melanogaster* metchnikowin reflects the species-dependent inhibition of succinate-coenzyme Q reductase. Sci Rep 7:1–9. <https://doi.org/10.1038/s41598-017-08407-x>
151. Kleino A, Silverman N (2014) The Drosophila IMD pathway in the activation of the humoral immune response. Dev Comp Immunol 42:25–35. <https://doi.org/10.1016/j.dci.2013.05.014>
152. Myllymäki H, Rämet M (2014) JAK/STAT Pathway in drosophila Immunity. Scand J Immunol 79:377–385. <https://doi.org/10.1111/sji.12170>
153. Valanne S, Wang J-H, Rämet M (2011) The Drosophila toll signaling pathway. J Immunol 186:649–656. <https://doi.org/10.4049/jimmunol.1002302>
154. Ashok Y (2009) Drosophila toll pathway: the new model. Sci Signal. <https://doi.org/10.1126/scisignal.252jc1>
155. Shia AKH, Glittenberg M, Thompson G, Weber AN, Reichhart JM, Ligoxygakis P (2009) Toll-dependent antimicrobial responses in Drosophila larval fat body require Spätzle secreted by haemocytes. J Cell Sci 122:4505–4515. <https://doi.org/10.1242/jcs.049155>
156. Mishima Y, Quintin J, Aimanianda V, Kellenberger C, Coste F, Clavaud C, Hetru C, Hoffmann JA, Latgé J-P, Ferrandon D, Roussel A (2009) The N-terminal domain of Drosophila Gram-negative binding protein 3 (GNBP3) defines a novel family of fungal pattern recognition receptors. J Biol Chem 284:28687–28697. <https://doi.org/10.1074/jbc.M109.034587>
157. Wang Y, Jiang H (2006) Interaction of beta-1,3-glucan with its recognition protein activates hemolymph proteinase 14, an initiation enzyme of the prophenoloxidase activation system in *Manduca sexta*. J Biol Chem 281:9271–9278. <https://doi.org/10.1074/jbc.M513797200>
158. Cherry S, Silverman N (2006) Host-pathogen interactions in drosophila: new tricks from an old friend. Nat Immunol. <https://doi.org/10.1038/ni1388>
159. Imler JL, Hoffmann JA (2002) Toll receptors in Drosophila: A family of molecules regulating development and immunity. Top. Microbiol. Immunol., Curr. https://doi.org/10.1007/978-3-642-59430-4_4
160. Stokes BA, Yadav S, Shokal U, Smith LC, Eleftherianos I (2015) Bacterial and fungal pattern recognition receptors in homologous innate signaling pathways of insects and mammals. Front Microbiol 6:19. <https://doi.org/10.3389/fmicb.2015.00019>
161. Shokal U, Eleftherianos I (2017) Evolution and function of thioester-containing proteins and the complement system in the innate immune response. Front Immunol 8:759
162. Kaneko T, Silverman N (2005) Bacterial recognition and signalling by the Drosophila IMD pathway. Cell Microbiol 7:461–469. <https://doi.org/10.1111/j.1462-5822.2005.00504.x>
163. Leulier F, Rodriguez A, Khush RS, Abrams JM, Lemaitre B (2000) The Drosophila caspase dredd is required to resist gram-negative bacterial infection. EMBO Rep 1:353–358. <https://doi.org/10.1093/embo-reports/kvd073>
164. Leulier F, Vidal S, Saigo K, Ueda R, Lemaitre B (2002) Inducible expression of double-stranded RNA reveals a role for dFADD in the regulation of the antibacterial response in Drosophila adults. Curr Biol 12:996–1000. [https://doi.org/10.1016/S0960-9822\(02\)00873-4](https://doi.org/10.1016/S0960-9822(02)00873-4)
165. Ertürk-Hasdemir D, Broemer M, Leulier F, Lane WS, Paquette N, Hwang D, Kim CH, Stöven S, Meier P, Silverman N (2009) Two roles for the Drosophila IKK complex in the activation of Relish and the induction of antimicrobial peptide genes. Proc Natl Acad Sci U S A 106:9779–9784. <https://doi.org/10.1073/pnas.0812022106>
166. O’Shea JJ, Plenge R (2012) JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 36:542–550. <https://doi.org/10.1016/j.immuni.2012.03.014>
167. Kiu H, Nicholson SE (2012) Biology and significance of the JAK/STAT signalling pathways. Growth Factors 30:88–106. <https://doi.org/10.3109/08977194.2012.660936>
168. Brown S, Hu N, Hombría JCG (2001) Identification of the first invertebrate interleukin JAK/STAT receptor, the Drosophila gene domeless. Curr Biol 11:1700–1705. [https://doi.org/10.1016/S0960-9822\(01\)00524-3](https://doi.org/10.1016/S0960-9822(01)00524-3)
169. Binari R, Perrimon N (1994) Stripe-specific regulation of pair-rule genes by hopscotch, a putative Jak family tyrosine kinase in Drosophila. Genes Dev 8:300–312. <https://doi.org/10.1101/gad.8.3.300>
170. Yan R, Small S, Desplan C, Dearolf CR, Darnell JE (1996) Identification of a Stat gene that functions in Drosophila development. Cell 84:421–430. [https://doi.org/10.1016/S0092-8674\(00\)81287-8](https://doi.org/10.1016/S0092-8674(00)81287-8)
171. Brown KL, Hancock REW (2006) Cationic host defense (antimicrobial) peptides. Curr Opin Immunol 18:24–30. <https://doi.org/10.1016/j.co.2005.11.004>
172. Andersson DI, Hughes D, Kubicek-Sutherland JZ (2016) Mechanisms and consequences of bacterial resistance to antimicrobial peptides. Drug Resist Updat. <https://doi.org/10.1016/j.drup.2016.04.002>
173. Di Somma A, Avitabile C, Cirillo A, Moretta A, Merlini A, Paduano L, Duilio A, Romanelli A (2020a) The antimicrobial peptide *Temporin L* impairs *E.coli* cell division by interacting with FtsZ and the divisome complex. Biochim. Biophys. Acta

- Gen. Subj. 1864(7):129606. <https://doi.org/10.1016/j.bbagen.2020.129606>
174. Rahnamaeian M, Cytryńska M, Zdybicka-Barabas A, Dobslaff K, Wiesner J, Twyman RM, Zuchner T, Sadd BM, Regoes RR, Schmid-Hempel P, Vilcinskas A (2015) Insect antimicrobial peptides show potentiating functional interactions against Gram-negative bacteria. *Proceedings Biol Sci* 282:20150293. <https://doi.org/10.1098/rspb.2015.0293>
175. Cociancich S, Ghazi A, Hetru C, Hoffmann JA, Letellier L (1993) Insect defensin, an inducible antibacterial peptide, forms voltage-dependent channels in *Micrococcus luteus*. *J Biol Chem* 268:19239–19245
176. Maget-Dana R, Ptak M (1997) Penetration of the insect defensin A into phospholipid monolayers and formation of defensin A-lipid complexes. *Biophys J* 73:2527–2533. [https://doi.org/10.1016/S0006-3495\(97\)78281-X](https://doi.org/10.1016/S0006-3495(97)78281-X)
177. Vizioli J, Richman AM, Uttenweiler-Joseph S, Blass C, Bulet P (2001) The defensin peptide of the malaria vector mosquito *Anopheles gambiae*: antimicrobial activities and expression in adult mosquitoes. *Insect Biochem Mol Biol* 31:241–248. [https://doi.org/10.1016/S0965-1748\(00\)00143-0](https://doi.org/10.1016/S0965-1748(00)00143-0)
178. Sato H, Feix JB (2006) Peptide-membrane interactions and mechanisms of membrane destruction by amphipathic α -helical antimicrobial peptides. *Biochim Biophys Acta - Biomembr* 1758:1245–1256. <https://doi.org/10.1016/j.bbamem.2006.02.021>
179. Goyal RK, Mattoo AK (2016) Plant antimicrobial peptides. In: Richard M Epand (eds) Host defense peptides and their potential as therapeutic agents. Springer, Cham, pp 111–136. https://doi.org/10.1007/978-3-319-32949-9_5
180. Efimova SS, Schagina LV, Ostroumova OS (2014) Channel-forming activity of cecropins in lipid bilayers: effect of agents modifying the membrane dipole potential. *Langmuir* 30:7884–7892. <https://doi.org/10.1021/la501549v>
181. Travkova OG, Moehwald H, Brezesinski G (2017) The interaction of antimicrobial peptides with membranes. *Adv Colloid Interface Sci.* <https://doi.org/10.1016/j.cis.2017.06.001>
182. Galdiero E, Lombardi L, Falanga A, Libralato G, Guida M, Carotenuto R (2019) Biofilms: novel strategies based on antimicrobial peptides. *Pharmaceutics*. <https://doi.org/10.3390/pharmaceutics11070322>
183. Lee H, Lim SI, Shin SH, Lim Y, Koh JW, Yang S (2019) Conjugation of cell-penetrating Peptides to antimicrobial peptides enhances antibacterial activity. *ACS Omega* 4:15694–15701. <https://doi.org/10.1021/acsomega.9b02278>
184. Sierra JM, Fusté E, Rabanal F, Vinuesa T, Viñas M (2017) An overview of antimicrobial peptides and the latest advances in their development. *Expert Opin Biol Ther.* <https://doi.org/10.1080/14712598.2017.1315402>
185. Chen J, Guan S-M, Sun W, Fu H (2016) Melittin, the major pain-producing substance of bee venom. *Neurosci Bull* 32:265–272. <https://doi.org/10.1007/s12264-016-0024-y>
186. Jamasbi E, Lucky SS, Li W, Hossain MA, Gopalakrishnakone P, Separovic F (2018) Effect of dimerized melittin on gastric cancer cells and antibacterial activity. *Amino Acids* 50:1101–1110. <https://doi.org/10.1007/s00726-018-2587-6>
187. Rady I, Siddiqui IA, Rady M, Mukhtar H (2017) Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy. *Cancer Lett.* <https://doi.org/10.1016/j.canlet.2017.05.010>
188. Di L (2015) Strategic approaches to optimizing peptide ADME properties. *AAPS J* 17:134–143. <https://doi.org/10.1208/s12248-014-9687-3>
189. Koehbach J (2017) Structure-activity relationships of insect defensins. *Front Chem.* <https://doi.org/10.3389/fchem.2017.00045>
190. Vlieghe P, Lisowski V, Martinez J, Khrestchatsky M (2010) Synthetic therapeutic peptides: science and market. *Drug Discov Today* 15:40–56
191. Knappe D, Cassone M, Inga Nollmann F, Otvos L, Hoffmann R (2014) Hydroxyproline substitutions stabilize non-glycosylated drosocin against serum proteases without challenging its antibacterial activity. *Protein Pept Lett* 21:321–329
192. Oliva R, Chino M, Pane K, Pistorio V, De Santis A, Pizzo E, D'Errico G, Pavone V, Lombardi A, Del Vecchio P, Notomista E, Nastri F, Petraccone L (2018) Exploring the role of unnatural amino acids in antimicrobial peptides. *Sci Rep* 8:1–16. <https://doi.org/10.1038/s41598-018-27231-5>
193. Amerikova M, Pencheva El-Tibi I, Maslarska V, Bozhanov S, Tachkov K (2019) Antimicrobial activity, mechanism of action, and methods for stabilisation of defensins as new therapeutic agents. *Biotechnol Biotechnol Equip* 33:671–682. <https://doi.org/10.1080/13102818.2019.1611385>
194. Fosgerau K, Hoffmann T (2015) Peptide therapeutics: Current status and future directions. *Drug Discov Today*. <https://doi.org/10.1016/j.drudis.2014.10.003>
195. Kumar P, Kizhakkedathu JN, Straus SK (2018) Antimicrobial peptides: diversity, mechanism of action and strategies to improve the activity and biocompatibility in vivo. *Biomolecules*. <https://doi.org/10.3390/biom8010004>
196. Wang G (2011) Post-translational modifications of natural antimicrobial peptides and strategies for peptide engineering. *Curr Biotechnol* 1:72–79. <https://doi.org/10.2174/2211551x11201010072>
197. Thorstholm L, Craik DJ (2012) Discovery and applications of naturally occurring cyclic peptides. *Drug Discov Today Technol* 9:e13–e21. <https://doi.org/10.1016/j.ddtec.2011.07.005>
198. Chen CH, Lu TK (2020) Development and challenges of antimicrobial peptides for therapeutic applications. *Antibiotics*. <https://doi.org/10.3390/antibiotics9010024>
199. Manteghi R, Pallagi E, Olajos G, Csóka I (2020) Pegylation and formulation strategy of anti-microbial peptide (AMP) according to the quality by design approach. *Eur J Pharm Sci* 144:105197. <https://doi.org/10.1016/j.ejps.2019.105197>
200. Shao C, Zhu Y, Lai Z, Tan P, Shan A (2019) Antimicrobial peptides with protease stability: progress and perspective. *Future Med Chem* 11:2047–2050. <https://doi.org/10.4155/fmc-2019-0167>
201. Souza BM, Mendes MA, Santos LD, Marques MR, César LMM, Almeida RNA, Pagnocca FC, Konno K, Palma MS (2005) Structural and functional characterization of two novel peptide toxins isolated from the venom of the social wasp *Polybia paulista*. *Peptides* 26:2157–2164. <https://doi.org/10.1016/j.peptides.2005.04.026>
202. Zhao Y, Zhang M, Qiu S, Wang J, Peng J, Zhao P, Zhu R, Wang H, Li Y, Wang K, Yan W, Wang R (2016) Antimicrobial activity and stability of the d-amino acid substituted derivatives of antimicrobial peptide polybia-MPI. *AMB Express*. <https://doi.org/10.1186/s13568-016-0295-8>
203. Jia F, Wang J, Peng J, Zhao P, Kong Z, Wang K, Yan W, Wang R (2017) D-amino acid substitution enhances the stability of antimicrobial peptide polybia-CP. *Acta Biochim Biophys Sin* 49:916–925. [https://doi.org/10.1093/ABBS/GMX091\(\(Shanghai\)\)](https://doi.org/10.1093/ABBS/GMX091((Shanghai)))
204. Falanga A, Nigro E, De Biasi MG, Daniele A, Morelli G, Galdiero S, Scudiero O (2017) Cyclic peptides as novel therapeutic microbicidies: engineering of human defensin mimetics. *Molecules*. <https://doi.org/10.3390/molecules22071217>
205. Mindt M, Risse JM, Gruß H, Sewald N, Eikmanns BJ, Wendisch VF (2018) One-step process for production of N-methylated amino acids from sugars and methylamine using recombinant

- Corynebacterium glutamicum* as biocatalyst. Sci Rep 8:12895. <https://doi.org/10.1038/s41598-018-31309-5>
206. Liu T, Zhu N, Zhong C, Zhu Y, Gou S, Chang L, Bao H, Liu H, Zhang Y, Ni J (2020) Effect of N-methylated and fatty acid conjugation on analogs of antimicrobial peptide Anoplin. Eur J Pharm Sci. <https://doi.org/10.1016/j.ejps.2020.105453>
207. Zhong C, Liu T, Gou S, He Y, Zhu N, Zhu Y, Wang L, Liu H, Zhang Y, Yao J, Ni J (2019) Design and synthesis of new N-terminal fatty acid modified-antimicrobial peptide analogues with potent in vitro biological activity. Eur J Med Chem 182:111636. <https://doi.org/10.1016/j.ejmch.2019.111636>
208. Ogus GK, Gilding EK, Huang YH, Poth AG, Jackson MA, Craik DJ (2020) Insecticidal diversity of butterfly pea (*Clitoria ternatea*) accessions. Ind Crops Prod 147:112214. <https://doi.org/10.1016/j.indcrop.2020.112214>
209. Koehbach J, Craik DJ (2019) The vast structural diversity of antimicrobial peptides. Trends Pharmacol Sci. <https://doi.org/10.1016/j.tips.2019.04.012>
210. Gobbo M, Benincasa M, Biondi L, Filira F, Gennaro R, Rocchi R, (2001) Cyclic Analogues of the insect antimicrobial peptides drosocin and apidaecin, In: Peptides: The wave of the future. Springer Netherlands, pp. 776–777. doi:https://doi.org/10.1007/978-94-010-0464-0_363.
211. Bulet P, Hetru C, Dimarcq JL, Hoffmann D (1999) Antimicrobial peptides in insects; structure and function. Dev Comp Immunol 23:329–344. [https://doi.org/10.1016/S0145-305X\(99\)00015-4](https://doi.org/10.1016/S0145-305X(99)00015-4)
212. Cybase [WWW Document], n.d. URL <http://www.cybase.org.au/>. Accessed 16 jul 2020
213. Bogdanowich-Knipp SJ, Chakrabarti S, Siahaan TJ, Williams TD, Dillman RK (1999) Solution stability of linear vs cyclic RGD peptides. J peptide res. 53(5):530–541
214. BaAMPs - Home [WWW Document], n.d. URL <http://www.baamps.it/>. Accessed 18 jul 2020
215. Di Luca M, Maccari G, Maisetta G, Batoni G (2015) BaAMPs: The database of biofilm-active antimicrobial peptides. Biofouling 31:193–199. <https://doi.org/10.1080/08927014.2015.1021340>
216. Di Somma, A., Moretta, A., Canè, C., Cirillo, A., Duilio, A., (2020b). Inhibition of bacterial biofilm formation, In: Bacterial Biofilms. IntechOpen.
217. Riool M, de Breij A, Drijfhout JW, Nibbering PH, Zaaij SAJ (2017) Antimicrobial peptides in biomedical device manufacturing. Front Chem 5:63. <https://doi.org/10.3389/fchem.2017.00063>
218. Hwang IS, Hwang JS, Hwang JH, Choi H, Lee E, Kim Y, Lee DG (2013) Synergistic effect and antibiofilm activity between the antimicrobial peptide coprisin and conventional antibiotics against opportunistic bacteria. Curr Microbiol 66:56–60. <https://doi.org/10.1007/s00284-012-0239-8>
219. Krishnan M, Choi J, Jang A, Kim Y (2020) A novel peptide antibiotic, Pro10-1D, designed from insect defensin shows anti-bacterial and anti-inflammatory activities in sepsis models. Int J Mol Sci 21:6216. <https://doi.org/10.3390/ijms21176216>
220. Kalsy M, Tonk M, Hardt M, Dobrindt U, Zdybicka-Barabas A, Cytrynska M, Vilcinskas A, Mukherjee K (2020) The insect antimicrobial peptide cecropin A disrupts uropathogenic *Escherichia coli* biofilms. NPJ biofilms and microbiomes 6(1):1–8. <https://doi.org/10.1038/s41522-020-0116-3>
221. Gordya N, Yakovlev A, Kruglikova A, Tulin D, Potolitsina E, Suborova T, Bordo D, Rosano C, Chernysh S (2017) Natural antimicrobial peptide complexes in the fighting of antibiotic resistant biofilms: *Calliphora vicina* medicinal maggots. PLoS ONE 12:e0173559. <https://doi.org/10.1371/journal.pone.0173559>
222. Chernysh S, Gordya N, Tulin D, Yakovlev A (2018) Biofilm infections between Scylla and Charybdis: interplay of host antimicrobial peptides and antibiotics. Infect Drug Resist 11:501–514. <https://doi.org/10.2147/IDR.S157847>
223. Wu Q, Patočka J, Kuča K (2018) Insect Antimicrobial Peptides, a Mini Review. Toxins. [\(Basel\)](https://doi.org/10.3390/toxins10110461) [\(Basel\)](https://doi.org/10.3390/toxins10110461)
224. Iwasaki T, Ishibashi J, Tanaka H, Sato M, Asaoka A, Taylor D, Yamakawa M (2009) Selective cancer cell cytotoxicity of enantiomeric 9-mer peptides derived from beetle defensins depends on negatively charged phosphatidylserine on the cell surface. Peptides 30:660–668. <https://doi.org/10.1016/j.peptides.2008.12.019>
225. Ratcliffe NA, Mello CB, Garcia ES, Butt TM, Azambuja P (2011) Insect natural products and processes: new treatments for human disease. Insect Biochem Mol Biol 41:747–769. <https://doi.org/10.1016/j.ibmb.2011.05.007>
226. Kono T, Watanabe M, Koyama K, Kishimoto T, Fukushima S, Sugimura T, Wakabayashi K (1999) Cytotoxic activity of pierisin, from the cabbage butterfly, *Pieris rapae*, in various human cancer cell lines. Cancer Lett 137:75–81
227. Orth JH, Schorch B, Boundy S, Ffrench-Constant R, Kubick S, Aktories K (2011) Cell-free synthesis and characterization of a novel cytotoxic pierisin-like protein from the cabbage butterfly *Pieris rapae*. Toxicon 57:199–207. <https://doi.org/10.1016/j.toxicon.2010.11.011>
228. Mylonakis E, Podsiadlowski L, Muhammed M, Vilcinskas A (2016) Diversity, evolution and medical applications of insect antimicrobial peptides. Philos Trans R Soc Lond B Biol Sci 371:20150290

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.